<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_RfUuFmn">Economic Evaluations of Digital Health Interventions for Patients With Heart Failure: Systematic Review</title>
				<funder>
					<orgName type="full">Universitas Padjadjaran, Bandung, Indonesia</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>PhD</roleName><forename type="first">Neily</forename><surname>Zakiyah</surname></persName>
							<email>neily.zakiyah@unpad.ac.id</email>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Pharmacology and Clinical Pharmacy , Faculty of Pharmacy , Universitas Padjadjaran , Bandung , Indonesia</note>
								<orgName type="department" key="dep1">Department of Pharmacology and Clinical Pharmacy</orgName>
								<orgName type="department" key="dep2">Faculty of Pharmacy</orgName>
								<orgName type="institution">Universitas Padjadjaran</orgName>
								<address>
									<settlement>Bandung</settlement>
									<country key="ID">Indonesia</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Center of Excellence for Pharmaceutical Care Innovation , Universitas Padjadjaran , Bandung , Indonesia</note>
								<orgName type="department">Center of Excellence for Pharmaceutical Care Innovation</orgName>
								<orgName type="institution">Universitas Padjadjaran</orgName>
								<address>
									<settlement>Bandung</settlement>
									<country key="ID">Indonesia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Dita</forename><surname>Marulin</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Pharmacology and Clinical Pharmacy , Faculty of Pharmacy , Universitas Padjadjaran , Bandung , Indonesia</note>
								<orgName type="department" key="dep1">Department of Pharmacology and Clinical Pharmacy</orgName>
								<orgName type="department" key="dep2">Faculty of Pharmacy</orgName>
								<orgName type="institution">Universitas Padjadjaran</orgName>
								<address>
									<settlement>Bandung</settlement>
									<country key="ID">Indonesia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mohammed</forename><surname>Alfaqeeh</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Pharmacology and Clinical Pharmacy , Faculty of Pharmacy , Universitas Padjadjaran , Bandung , Indonesia</note>
								<orgName type="department" key="dep1">Department of Pharmacology and Clinical Pharmacy</orgName>
								<orgName type="department" key="dep2">Faculty of Pharmacy</orgName>
								<orgName type="institution">Universitas Padjadjaran</orgName>
								<address>
									<settlement>Bandung</settlement>
									<country key="ID">Indonesia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Irma</forename><forename type="middle">Melyani</forename><surname>Puspitasari</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Pharmacology and Clinical Pharmacy , Faculty of Pharmacy , Universitas Padjadjaran , Bandung , Indonesia</note>
								<orgName type="department" key="dep1">Department of Pharmacology and Clinical Pharmacy</orgName>
								<orgName type="department" key="dep2">Faculty of Pharmacy</orgName>
								<orgName type="institution">Universitas Padjadjaran</orgName>
								<address>
									<settlement>Bandung</settlement>
									<country key="ID">Indonesia</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Center of Excellence for Pharmaceutical Care Innovation , Universitas Padjadjaran , Bandung , Indonesia</note>
								<orgName type="department">Center of Excellence for Pharmaceutical Care Innovation</orgName>
								<orgName type="institution">Universitas Padjadjaran</orgName>
								<address>
									<settlement>Bandung</settlement>
									<country key="ID">Indonesia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Keri</forename><surname>Lestari</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Pharmacology and Clinical Pharmacy , Faculty of Pharmacy , Universitas Padjadjaran , Bandung , Indonesia</note>
								<orgName type="department" key="dep1">Department of Pharmacology and Clinical Pharmacy</orgName>
								<orgName type="department" key="dep2">Faculty of Pharmacy</orgName>
								<orgName type="institution">Universitas Padjadjaran</orgName>
								<address>
									<settlement>Bandung</settlement>
									<country key="ID">Indonesia</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Center of Excellence for Pharmaceutical Care Innovation , Universitas Padjadjaran , Bandung , Indonesia</note>
								<orgName type="department">Center of Excellence for Pharmaceutical Care Innovation</orgName>
								<orgName type="institution">Universitas Padjadjaran</orgName>
								<address>
									<settlement>Bandung</settlement>
									<country key="ID">Indonesia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Ka</forename><forename type="middle">Keat</forename><surname>Lim</surname></persName>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Department of Population Health Sciences , Faculty of Life Sciences and Medicine , King&apos;s College London , London , United Kingdom</note>
								<orgName type="department" key="dep1">Department of Population Health Sciences</orgName>
								<orgName type="department" key="dep2">Faculty of Life Sciences and Medicine</orgName>
								<orgName type="institution">King&apos;s College London</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Julia</forename><surname>Fox-Rushby</surname></persName>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Department of Population Health Sciences , Faculty of Life Sciences and Medicine , King&apos;s College London , London , United Kingdom</note>
								<orgName type="department" key="dep1">Department of Population Health Sciences</orgName>
								<orgName type="department" key="dep2">Faculty of Life Sciences and Medicine</orgName>
								<orgName type="institution">King&apos;s College London</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Â©neily</forename><surname>Zakiyah</surname></persName>
						</author>
						<author>
							<affiliation key="aff3">
								<note type="raw_affiliation">Department of Pharmacology and Clinical Pharmacy Faculty of Pharmacy Universitas Padjadjaran Jl. Raya Bandung Sumedang KM 21 Bandung , 45363 Indonesia</note>
								<orgName type="department">Department of Pharmacology and Clinical Pharmacy Faculty of Pharmacy</orgName>
								<orgName type="institution">Universitas Padjadjaran Jl</orgName>
								<address>
									<addrLine>Raya Bandung Sumedang KM 21</addrLine>
									<postCode>45363</postCode>
									<settlement>Bandung</settlement>
									<country key="ID">Indonesia</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_jr6m2eG">Economic Evaluations of Digital Health Interventions for Patients With Heart Failure: Systematic Review</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">964E4B7784F39B046835910495827CDD</idno>
					<idno type="DOI">10.2196/53500</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T08:27+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term xml:id="_54ADWVW">digital health</term>
					<term xml:id="_3zMMzbQ">telemonitoring</term>
					<term xml:id="_YtS5f3F">telehealth</term>
					<term xml:id="_h429t7e">heart failure</term>
					<term xml:id="_2aj3vWp">cost-effectiveness</term>
					<term xml:id="_Cqt2Kx5">systematic review</term>
					<term xml:id="_8Hp4URx">mobile phone</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_B9DKdbF"><p xml:id="_SEXCU3q"><s xml:id="_8syvFxc">Background: Digital health interventions (DHIs) have shown promising results in enhancing the management of heart failure (HF).</s><s xml:id="_z9z77hS">Although health care interventions are increasingly being delivered digitally, with growing evidence on the potential cost-effectiveness of adopting them, there has been little effort to collate and synthesize the findings.</s></p><p xml:id="_mEPmVXY"><s xml:id="_JWvHzW4">Objective: This study's objective was to systematically review the economic evaluations that assess the adoption of DHIs in the management and treatment of HF.</s></p><p xml:id="_xuTpY2r"><s xml:id="_czPzBRY">Methods: A systematic review was conducted using 3 electronic databases: PubMed, EBSCOhost, and Scopus.</s><s xml:id="_eE8W25w">Articles reporting full economic evaluations of DHIs for patients with HF published up to July 2023 were eligible for inclusion.</s><s xml:id="_jRBMjaM">Study characteristics, design (both trial based and model based), input parameters, and main results were extracted from full-text articles.</s><s xml:id="_WEYKZRx">Data synthesis was conducted based on the technologies used for delivering DHIs in the management of patients with HF, and the findings were analyzed narratively.</s><s xml:id="_uXtpHVD">The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were followed for this systematic review.</s><s xml:id="_Jzrn9ku">The reporting quality of the included studies was evaluated using the CHEERS (Consolidated Health Economic Evaluation Reporting Standards) guidelines.</s></p><p xml:id="_xNSbmeW"><s xml:id="_aHYEnzP">Results: Overall, 27 economic evaluations were included in the review.</s><s xml:id="_pRxFx9x">The economic evaluations were based on models (13/27, 48%), trials (13/27, 48%), or a combination approach (1/27, 4%).</s><s xml:id="_zmFfgUZ">The devices evaluated included noninvasive remote monitoring devices (eg, home telemonitoring using digital tablets or specific medical devices that enable transmission of physiological data), telephone support, mobile apps and wearables, remote monitoring follow-up in patients with implantable medical devices, and videoconferencing systems.</s><s xml:id="_nqDThds">Most of the studies (24/27, 89%) used cost-utility analysis.</s><s xml:id="_SBuejTf">The majority of the studies (25/27, 93%) were conducted in high-income countries, particularly European countries (16/27, 59%) such as the United Kingdom and the Netherlands.</s><s xml:id="_C47qRTE">Mobile apps and wearables, remote monitoring follow-up in patients with implantable medical devices, and videoconferencing systems yielded cost-effective results or even emerged as dominant strategies.</s><s xml:id="_sy3T4cH">However, conflicting results were observed, particularly in noninvasive remote monitoring devices and telephone support.</s><s xml:id="_HZ4dP3z">In 15% (4/27) of the studies, these DHIs were found to be less costly and more effective than the comparators (ie, dominant), while 33% (9/27) reported them to be more costly but more effective with incremental cost-effectiveness ratios below the respective willingness-to-pay thresholds (ie, cost-effective).</s><s xml:id="_V4TSMpu">Furthermore, in 11% (3/27) of the studies, noninvasive remote monitoring devices and telephone support were either above the willingness-to-pay thresholds or more costly than, yet as effective as, the comparators (ie, not cost-effective).</s><s xml:id="_McPjBMB">In terms of reporting quality, the studies were classified as good (20/27, 74%), moderate (6/27, 22%), or excellent (1/27, 4%).</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="11" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="12" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="13" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="14" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="15" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="16" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="17" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="18" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="19" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
		<surface n="20" ulx="0.0" uly="0.0" lrx="595.276" lry="841.89"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_nAYBn6K">Introduction</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_sC4RG6U">Background</head><p xml:id="_sU6F7Xw"><s xml:id="_h2FQem6">Heart failure (HF) is a complex and potentially fatal condition affecting approximately 26 million people worldwide and is associated with substantial morbidity and mortality <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>.</s><s xml:id="_JuV4WDm">The global impact of HF also imposes a significant economic burden, affecting patients and their families as well as communities <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>.</s><s xml:id="_aZhPWTK">Data from low-and middle-income countries (LMICs) indicate that mortality rates in patients with HF are higher in LMICs than in high-income countries (HICs) <ref type="bibr" target="#b2">[3]</ref>.</s><s xml:id="_9J35nZX">The overall estimated 1-year mortality rate for patients with HF in LMICs is 16.5% <ref type="bibr" target="#b2">[3]</ref> compared to 8.3% in HICs.</s><s xml:id="_wrtmd4a">People living with HF also experience a significant decline in health-related quality of life (HRQoL) <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b4">5]</ref>.</s></p><p xml:id="_NV72B6u"><s xml:id="_CawmSjs">The growing availability of life-saving and evidence-based treatments, along with increasing life expectancy, suggests that there will be an increase in the prevalence of HF over time.</s><s xml:id="_3g3ynBp">This is attributed to the improved survival rates after an HF diagnosis and the aging population <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b6">7]</ref>.</s><s xml:id="_KBTVFpT">The rise in HF prevalence is leading to an increase in annual health care costs.</s><s xml:id="_Mda6rXz">In 2012, the estimated global annual cost of HF reached US $108 billion, with direct costs estimated at US $65 billion and indirect costs estimated at US $43 billion <ref type="bibr" target="#b7">[8]</ref>.</s><s xml:id="_cmfQDjp">Considering a projected 22% increase in the cost of cardiovascular diseases (CVDs), HF-related expenses alone could potentially reach US $132 billion by 2030 <ref type="bibr" target="#b8">[9]</ref>.</s><s xml:id="_ZdK3dYv">Despite significant improvements in outcomes with medical therapy <ref type="bibr" target="#b6">[7]</ref>, readmission rates for patients hospitalized for HF are still high (ie, 50% within 6 months of discharge) <ref type="bibr" target="#b9">[10,</ref><ref type="bibr" target="#b10">11]</ref>.</s><s xml:id="_KhtQ9hY">Hospitalization rates have been shown to be correlated with disease severity, mortality, and lower HRQoL <ref type="bibr" target="#b4">[5]</ref>.</s></p><p xml:id="_Qe8cPcD"><s xml:id="_gncPxrC">Considering the prevalence of HF and its substantial financial burden, there has been a global focus on cost-effective health care interventions aimed at providing effective and efficient support to patients, as well as a growing focus on the application of digital health interventions (DHIs), driven by the advanced integration of IT and mobile internet in health care practices <ref type="bibr" target="#b11">[12]</ref>.</s><s xml:id="_SQYKYrh">The broad scope of digital health includes telehealth, teleconsultation, and telemonitoring using smartphone apps; telephone support; videoconferencing; noninvasive remote monitoring devices; wearables; implantable devices; and sensors <ref type="bibr" target="#b12">[13,</ref><ref type="bibr" target="#b13">14]</ref>.</s><s xml:id="_yFNtdkh">In addition, emerging fields such as advanced computing sciences in big data, genomics for personalized medicine, and artificial intelligence have been recognized as DHIs <ref type="bibr" target="#b12">[13,</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref>.</s><s xml:id="_WfBxMGz">DHIs are used by providers and other stakeholders to enhance access, reduce inefficiencies and costs, improve quality, and potentially incorporate personalized medicine to improve patients' clinical outcomes <ref type="bibr" target="#b13">[14]</ref>.</s></p><p xml:id="_M5FNJ5W"><s xml:id="_MHqwqZu">By using DHIs in the management of HF, it may be possible to prevent the progression of a patient's condition and potentially reduce health care costs <ref type="bibr" target="#b17">[18]</ref>.</s><s xml:id="_BxKXCQs">HF is a chronic condition in which people often experience episodic deterioration.</s><s xml:id="_ZVQJEFh">Improvement in disease monitoring can enable prompt identification of patient deterioration and facilitate timely interventions to restabilize the syndrome <ref type="bibr" target="#b18">[19,</ref><ref type="bibr" target="#b19">20]</ref>.</s><s xml:id="_gyvmMYN">Implementing DHIs such as teleconsultation and remote monitoring can reduce unnecessary hospital visits, provide continuous disease monitoring, develop effective disease management, and improve clinical outcomes.</s><s xml:id="_qYRGUgp">However, because the landscape of DHIs is evolving rapidly, regulators, reimbursement authorities, and health care professionals often face challenges in evaluating the value of these technologies, as reflected in current recommendations in the international guidelines of the European Society of Cardiology and the American College of Cardiology <ref type="bibr" target="#b18">[19,</ref><ref type="bibr" target="#b19">20]</ref>.</s><s xml:id="_g6zxTHB">Skepticism regarding the value of DHIs is partly driven by the limited large-scale studies that demonstrate a consistent impact and effectiveness <ref type="bibr" target="#b17">[18]</ref>.</s><s xml:id="_hB5fWFW">Despite the growth in, and the integration of, DHIs in recent years, evidence from economic evaluations is limited.</s><s xml:id="_WGyTt4Y">One systematic review found that telemedicine improved clinical outcomes and resulted in cost savings for patients with CVDs, concluding that it is more cost-effective than standard of care (SoC) <ref type="bibr" target="#b20">[21]</ref>.</s><s xml:id="_SZzamSS">This mirrors the broad findings of 2 other systematic reviews covering a diverse range of DHIs <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b22">23]</ref>.</s><s xml:id="_n3mnpUw">However, 2 reviews were more focused on CVDs than on HF <ref type="bibr" target="#b20">[21,</ref><ref type="bibr" target="#b21">22]</ref>, with 1 review not including search terms related to HF <ref type="bibr" target="#b20">[21]</ref>; 2 reviews focused on either economic models or randomized controlled trials (RCTs) but not both <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b22">23]</ref>; and 2 reviews only considered a limited range of DHIs <ref type="bibr" target="#b20">[21,</ref><ref type="bibr" target="#b22">23]</ref>.</s><s xml:id="_mwTdwvV">To date, no comprehensive systematic review has been conducted to evaluate the economic evaluations of DHIs specifically in patients with HF, considering evidence from both models and RCTs.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_F6sV7Bk">Objectives</head><p xml:id="_WSWKXvB"><s xml:id="_dUXEYDs">The aim of this systematic review was to provide an overview and summarize published economic evaluations of DHIs in patients with HF that consider both models and analyses conducted alongside trial-based evaluations.</s><s xml:id="_rHd9vJc">Demonstrating the cost-effectiveness of DHIs will contribute to a better understanding of the potential economic implications of adopting these approaches.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ZUAnvg7">Methods</head><p xml:id="_HrKR2HS"><s xml:id="_sh6uxyJ">This systematic review was conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines <ref type="bibr" target="#b23">[24]</ref>, and the review was registered in PROSPERO <ref type="bibr" target="#b24">[25]</ref>.</s><s xml:id="_JFHrFS9">The PRISMA checklist is provided in Multimedia Appendix 1.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ruuT6hU">Search Strategy</head><p xml:id="_4sQznDT"><s xml:id="_QP8fuUb">A systematic search was performed across 3 major electronic databases (PubMed, EBSCOhost, and Scopus) to identify economic evaluations of DHIs for patients with HF.</s><s xml:id="_DPSCvGX">Medical Subject Headings terms and text words related to "heart failure," "digital health," and "economic evaluation" were used to search from database inception to July 2023.</s><s xml:id="_ctS3cu9">Terms were combined using "OR" and "AND."</s><s xml:id="_bXgMakm">Full details are provided in Multimedia Appendix 2.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_NWTQeaa">Study Selection</head><p xml:id="_SPVYzQx"><s xml:id="_tNbKSze">The search results were exported to Mendeley Reference Manager (Elsevier Ltd) and checked for duplicates.</s><s xml:id="_A4qxtdS">Two reviewers (NZ and DM) independently performed a full-text review of the chosen articles after the preliminary title and abstract screening, using the inclusion and exclusion criteria detailed in Textbox 1.</s></p><p xml:id="_td7JajP"><s xml:id="_SyxKxwQ">Any disagreements were discussed, and a third reviewer was consulted for arbitration to arrive at a consensus if required.</s><s xml:id="_nukEnEh">References were also searched for further relevant papers during the full-text reviews.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_byEZ4kt">Textbox 1. Inclusion and exclusion criteria.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_9wYGK8x">Inclusion criteria</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_eXhseeB">â¢</head><p xml:id="_xmQExZE"><s xml:id="_wVq3rcb">Type of study: a full economic evaluation of digital health interventions (DHIs) for the management of patients with heart failure (HF), categorized as cost-benefit analysis, cost-utility analysis, cost-effectiveness analysis, and cost-minimization analysis</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_YZkBV9e">â¢</head><p xml:id="_NRFSU2Y"><s xml:id="_h9kjmyJ">Intervention: any DHI for patients with HF comprising a digital intervention for transmitting medical information to improve patients' health status (DHIs are a broad concept encompassing eHealth, which refers to the application of information and communications technology in support of health and health-related fields; this includes the use of mobile devices such as smartphones and patient monitoring devices in medical and public health practices, commonly known as mobile health.</s><s xml:id="_a4M9Bej">DHIs also comprise emerging domains such as advanced computing sciences in big data, genomics, and artificial intelligence <ref type="bibr" target="#b12">[13,</ref><ref type="bibr" target="#b25">26]</ref>.</s><s xml:id="_pPDacbF">Standard of care was defined as the standard multidisciplinary management program <ref type="bibr" target="#b18">[19,</ref><ref type="bibr" target="#b19">20]</ref>, which includes regular planned follow-up for the purpose of safety and optimal drug dosing (standard of care with or without drug or exercise prescription), early detection of decompensation, and impact on disease progression that requires modification of the intervention or treatment regimen)</s></p><p xml:id="_RuvHrDu"><s xml:id="_4CsxkXn">â¢ Participants: adult patients with HF (aged â¥18 y)</s></p><p xml:id="_YaSrPxR"><s xml:id="_h23Rr8t">â¢ Time limits: searches were conducted for relevant articles published from the beginning of database entries to July 2023</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_NyBbMrg">Exclusion criteria</head><p xml:id="_MhBWcQM"><s xml:id="_qwQtn5S">â¢ Non-English studies, experimental and observational studies without economic evaluation, studies that did not report outcomes specific to HF, reviews, conference abstracts, and editorials</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_wVPjtH6">Data Extraction</head><p xml:id="_auNk6tg"><s xml:id="_s4KeAbE">Two reviewers conducted data extraction from the full-text articles independently using a predetermined form covering general study characteristics (author, country, and year of publication), study design (type of economic evaluation, perspective, model type, time horizon, discount rate, intervention vs comparator, outcome measures, and sensitivity analysis), primary outcomes, and quality of reporting.</s><s xml:id="_MTy7Xh9">Only results related to DHIs for patients with HF were extracted when many interventions were evaluated.</s><s xml:id="_ekC6XWV">The primary outcomes collected were the cost-benefit ratio, cost savings, and cost-effectiveness of DHIs.</s><s xml:id="_d5nMXZc">Cost-effectiveness is represented by the incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) gained or per intermediate outcome measure such as mortality or hospitalization.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_q8fh4wH">Ethical Considerations</head><p xml:id="_pPPN7Bv"><s xml:id="_t4eM6H4">As we exclusively used published studies for this systematic review and did not involve patients or the public or conduct any patient interviews, a review by, or approval from, an institutional review board was not required.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_jsMHFCV">Quality of Reporting</head><p xml:id="_E2zxWVm"><s xml:id="_ZHDQhjg">The CHEERS (Consolidated Health Economic Evaluation Reporting Standards) checklist was used to assess the reporting quality of each study <ref type="bibr" target="#b26">[27]</ref>.</s><s xml:id="_AKTzfMv">The CHEERS checklist includes 28 items, with 1 point assigned to each item when the quality criterion is fulfilled (and 0 points for not entirely conforming to the relevant criterion) to generate a total score, with 28 (representing 100%) being the maximum score.</s><s xml:id="_vVUSQsh">On the basis of the scores, studies are classified into 4 quality categories: excellent (score: 100%), good (score: 75%-99%), moderate (score: 50%-74%), and low (score: â¤49%) <ref type="bibr" target="#b27">[28]</ref>.</s><s xml:id="_apvFQeh">This reflects reporting quality rather than a view of overall importance or methodological quality.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_7ARdQXq">Analysis and Presentation of Results</head><p xml:id="_xuZFnXw"><s xml:id="_FSm9AM3">The results are presented in a range of narrative tables by study.</s></p><p xml:id="_BHp37vW"><s xml:id="_VrXJvBg">The included studies were categorized by the device or technology used for delivering DHIs in managing patients with HF (ie, noninvasive remote monitoring devices, telephone support, mobile apps and wearables, remote monitoring follow-up in patients with implantable medical devices, and videoconferencing systems) [13,17].</s><s xml:id="_wYdVzqY">Secondary categorization separates results by model-based and RCT-based studies.</s><s xml:id="_yEBd5pX">Money values were converted to 2023 US dollars using the Campbell and Cochrane Economics Methods Group-Evidence for Policy &amp; Practice Information Centre Cost Converter <ref type="bibr" target="#b28">[29]</ref>.</s><s xml:id="_EFbTScE">If the study did not specify the costing year, publication year was assumed to be the year of costing.</s><s xml:id="_JWyMZZt">A 3Ã3 permutation matrix shows how each intervention's outcomes (improved, worsened, or unchanged) and costs (increased, decreased, or unchanged) compare with those of its comparator in the studies <ref type="bibr" target="#b29">[30]</ref>.</s><s xml:id="_rCVHWNy">This permutation matrix also splits the findings by DHI type.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_xrNeq2a">Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_fa7mQ7J">Study Identification</head><p xml:id="_nM5AuNV"><s xml:id="_Ugkn7SN">The initial search retrieved 365 studies, of which 7 (1.9%)</s><s xml:id="_QmDRv8G">duplicates were excluded.</s><s xml:id="_49wqBsH">Of the 358 studies left, the title and abstract screening process excluded 296 (82.7%).</s><s xml:id="_m33S6Z5">After a full-text screening of the remaining 62 studies, we excluded 37 (60%; 21/37, 57% were classified as partial economic evaluations, such as cost analysis, containing only descriptions of costs; 10/37, 27% did not report outcomes specifically for HF; and 6/37, 16% were conference abstracts), resulting in 25 (40%) out of 62 studies for inclusion in the analysis.</s><s xml:id="_dZqfV3K">Two extra studies were identified from reference reviews; thus, 27 studies  were included in this systematic review.</s></p><p xml:id="_YbdjsxK"><s xml:id="_KDUYwf4">The selection process and flow diagram for the identification of studies are depicted in Figure <ref type="figure" target="#fig_0">1</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_dCKCy3p">Study Characteristics and Design</head><p xml:id="_bF5ENyg"><s xml:id="_XkcjS5c">Table <ref type="table" target="#tab_2">1</ref> summarizes the general characteristics of the included studies.</s><s xml:id="_AWtgNkR">Of the 27 studies, 13 (48%) were conducted using a decision analytical model <ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b39">40,</ref><ref type="bibr" target="#b46">[47]</ref><ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b48">[49]</ref><ref type="bibr" target="#b49">[50]</ref><ref type="bibr" target="#b50">[51]</ref>, 13 (48%) used trial-based data <ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b40">[41]</ref><ref type="bibr" target="#b41">[42]</ref><ref type="bibr" target="#b42">[43]</ref><ref type="bibr" target="#b43">[44]</ref><ref type="bibr" target="#b44">[45]</ref><ref type="bibr" target="#b45">[46]</ref><ref type="bibr" target="#b53">[54]</ref><ref type="bibr" target="#b54">[55]</ref><ref type="bibr" target="#b55">[56]</ref><ref type="bibr" target="#b56">[57]</ref>, and 1 (4%) used a combination of both <ref type="bibr" target="#b40">[41]</ref>.</s><s xml:id="_Wuyjcby">The majority of the studies (25/27, 93%) were from HICs.</s><s xml:id="_TdeBwQ3">Of the 27 studies, 6 (22%) were from the United States <ref type="bibr" target="#b33">[34,</ref><ref type="bibr" target="#b42">43,</ref><ref type="bibr" target="#b43">44,</ref><ref type="bibr" target="#b50">[51]</ref><ref type="bibr" target="#b51">[52]</ref><ref type="bibr" target="#b52">[53]</ref>; 3 (11%) each from the Netherlands <ref type="bibr" target="#b32">[33,</ref><ref type="bibr" target="#b36">37,</ref><ref type="bibr" target="#b39">40]</ref> and the United Kingdom <ref type="bibr" target="#b31">[32,</ref><ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b49">50]</ref>; 2 (7%) each from Germany <ref type="bibr" target="#b35">[36,</ref><ref type="bibr" target="#b37">38]</ref>, Brazil <ref type="bibr" target="#b40">[41,</ref><ref type="bibr" target="#b44">45]</ref>, Canada <ref type="bibr" target="#b41">[42,</ref><ref type="bibr" target="#b47">48]</ref>, Italy <ref type="bibr" target="#b54">[55,</ref><ref type="bibr" target="#b55">56]</ref>, and Spain <ref type="bibr" target="#b45">[46,</ref><ref type="bibr" target="#b48">49]</ref>; and 1 (4%) each from Australia <ref type="bibr" target="#b56">[57]</ref>, Poland <ref type="bibr" target="#b53">[54]</ref>, France <ref type="bibr" target="#b30">[31]</ref>, Hong Kong <ref type="bibr" target="#b46">[47]</ref>, and Denmark <ref type="bibr" target="#b38">[39]</ref>.</s><s xml:id="_f45D3Ek">Of the 27 studies, 24 (89%) conducted a cost-utility analysis with cost and QALY as the outcome measures <ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b39">[40]</ref><ref type="bibr" target="#b41">[42]</ref><ref type="bibr" target="#b42">[43]</ref><ref type="bibr" target="#b43">[44]</ref><ref type="bibr" target="#b44">[45]</ref><ref type="bibr" target="#b45">[46]</ref><ref type="bibr" target="#b46">[47]</ref><ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b48">[49]</ref><ref type="bibr" target="#b49">[50]</ref><ref type="bibr" target="#b50">[51]</ref><ref type="bibr" target="#b53">54,</ref><ref type="bibr" target="#b55">56,</ref><ref type="bibr" target="#b56">57]</ref>, 2 (7%) conducted a cost-effectiveness analysis (1/2, 50% with hospital readmission as the outcome measure <ref type="bibr" target="#b40">[41]</ref> and 1/2, 50% with number of days alive and neither in hospital nor in inpatient care as the outcome measure <ref type="bibr" target="#b35">[36]</ref>), and 1 (3%) conducted a cost-minimization analysis <ref type="bibr" target="#b54">[55]</ref>.</s><s xml:id="_EHjQcfE">Of the 27 studies, 15 (56%) used a time horizon of &gt;1 year (3/15, 20% were RCTs) <ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b39">40,</ref><ref type="bibr" target="#b43">44,</ref><ref type="bibr" target="#b44">45,</ref><ref type="bibr" target="#b46">47,</ref><ref type="bibr" target="#b47">48,</ref><ref type="bibr" target="#b49">[50]</ref><ref type="bibr" target="#b50">[51]</ref><ref type="bibr" target="#b51">[52]</ref><ref type="bibr" target="#b52">[53]</ref><ref type="bibr" target="#b53">[54]</ref>; the time horizon in 6 (22%) studies was â¤1 year (all were RCTs) <ref type="bibr" target="#b35">[36,</ref><ref type="bibr" target="#b38">39,</ref><ref type="bibr" target="#b40">[41]</ref><ref type="bibr" target="#b41">[42]</ref><ref type="bibr" target="#b42">[43]</ref><ref type="bibr" target="#b45">46]</ref>; 6 (22%) did not state the time horizon (5/6, 83% were RCTs and 1/6, 17% was model based) <ref type="bibr" target="#b36">[37,</ref><ref type="bibr" target="#b37">38,</ref><ref type="bibr" target="#b48">49,</ref><ref type="bibr" target="#b54">[55]</ref><ref type="bibr" target="#b55">[56]</ref><ref type="bibr" target="#b56">[57]</ref>.</s><s xml:id="_jKtmeuv">Of the 27 studies, 15 (56%) received grants from public organizations <ref type="bibr" target="#b30">[31,</ref><ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b35">36,</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b39">[40]</ref><ref type="bibr" target="#b40">[41]</ref><ref type="bibr" target="#b42">43,</ref><ref type="bibr" target="#b43">44,</ref><ref type="bibr" target="#b45">46,</ref><ref type="bibr" target="#b48">49,</ref><ref type="bibr" target="#b53">54,</ref><ref type="bibr" target="#b55">56,</ref><ref type="bibr" target="#b56">57]</ref>, 3 (11%) received funding from industry <ref type="bibr" target="#b36">[37,</ref><ref type="bibr" target="#b49">50,</ref><ref type="bibr" target="#b50">51]</ref>, 2 (7%) received no funding <ref type="bibr" target="#b41">[42,</ref><ref type="bibr" target="#b54">55]</ref>, and 7 (26%) did not declare their funding source <ref type="bibr" target="#b32">[33,</ref><ref type="bibr" target="#b33">34,</ref><ref type="bibr" target="#b44">45,</ref><ref type="bibr" target="#b46">47,</ref><ref type="bibr" target="#b47">48,</ref><ref type="bibr" target="#b51">52,</ref><ref type="bibr" target="#b52">53]</ref>.</s></p><p xml:id="_dF3qgEx"><s xml:id="_NmmrtE5">A little more than half of the studies (14/27, 52%) measured effectiveness with HRQoL (or utilities) using a patient-based EQ-5D instrument <ref type="bibr" target="#b30">[31,</ref><ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b33">34,</ref><ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b39">[40]</ref><ref type="bibr" target="#b47">48,</ref><ref type="bibr" target="#b49">[50]</ref><ref type="bibr" target="#b50">[51]</ref><ref type="bibr" target="#b51">[52]</ref><ref type="bibr" target="#b52">[53]</ref><ref type="bibr" target="#b55">56,</ref><ref type="bibr" target="#b56">57]</ref>.</s><s xml:id="_9NN5uw4">Other studies used the generic Short Form Health Survey-36 with norm-based scoring <ref type="bibr" target="#b41">[42,</ref><ref type="bibr" target="#b43">44,</ref><ref type="bibr" target="#b53">54]</ref>, the Minnesota Living with Heart Failure Questionnaire <ref type="bibr" target="#b44">[45]</ref>, or a combination of both <ref type="bibr" target="#b35">[36,</ref><ref type="bibr" target="#b42">43]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_xJUuk2J">XSL â¢ FO</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Ba3Pvrv">RenderX</head><p xml:id="_XXJ3Z9G"><s xml:id="_dgEEy6Z">All studies included the direct costs of DHIs, such as the costs of the DHIs, inpatient and outpatient costs, monitoring and follow-up costs, and medication costs.</s><s xml:id="_RWNFFGu">Some of the studies (12/27, 44%) included nonmedical direct costs, such as travel and transportation costs <ref type="bibr" target="#b32">[33,</ref><ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b37">38,</ref><ref type="bibr" target="#b40">41,</ref><ref type="bibr" target="#b42">43,</ref><ref type="bibr" target="#b45">46,</ref><ref type="bibr" target="#b49">50,</ref><ref type="bibr" target="#b54">55]</ref>. Studies that used a societal perspective (6/27, 22%) also included indirect costs, such as productivity losses <ref type="bibr" target="#b32">[33,</ref><ref type="bibr" target="#b37">38,</ref><ref type="bibr" target="#b42">43,</ref><ref type="bibr" target="#b45">46,</ref><ref type="bibr" target="#b54">55,</ref><ref type="bibr" target="#b55">56]</ref>.</s><s xml:id="_hk7G9Su">Details on the perspectives and included costs are provided in Multimedia Appendix 3 <ref type="bibr" target="#b18">[19,</ref><ref type="bibr" target="#b19">20,</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_MpECMed">Cost-Effectiveness of Devices or Technologies Used for Delivering DHIs in the Management of Patients With HF</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_m4CNJrg">Overview</head><p xml:id="_Dhm5W2G"><s xml:id="_g26QtkM">This subsection describes the nature of the DHIs assessed for cost-effectiveness and presents cost-effectiveness findings by type of DHI in order of the number of studies identified.</s><s xml:id="_YRrMVFn">Details on summaries and outcomes from the studies are provided in Table <ref type="table" target="#tab_3">2</ref>; and relative costs, effects, and main outcomes are presented in Table <ref type="table" target="#tab_6">3</ref>. Overall, of the 27 studies, 24 (89%) found the DHIs to be cost-effective <ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b39">[40]</ref><ref type="bibr" target="#b40">[41]</ref><ref type="bibr" target="#b41">[42]</ref><ref type="bibr" target="#b42">[43]</ref><ref type="bibr" target="#b44">[45]</ref><ref type="bibr" target="#b45">[46]</ref><ref type="bibr" target="#b46">[47]</ref><ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b48">[49]</ref><ref type="bibr" target="#b49">[50]</ref><ref type="bibr" target="#b50">[51]</ref><ref type="bibr" target="#b51">[52]</ref><ref type="bibr" target="#b52">[53]</ref><ref type="bibr" target="#b53">[54]</ref><ref type="bibr" target="#b54">[55]</ref><ref type="bibr" target="#b55">[56]</ref><ref type="bibr" target="#b56">[57]</ref>, whereas 3 (11%) were not cost-effective, particularly home telemonitoring (HTM) and telephone support <ref type="bibr" target="#b34">[35,</ref><ref type="bibr" target="#b35">36,</ref><ref type="bibr" target="#b43">44]</ref>.</s><s xml:id="_v94nG6v">Remote monitoring follow-up in patients with implantable medical devices (n=7) Model based Good (score: 25/28, 89%) 32,351 â¢ 31,177/QALY 3.5 10 y United Kingdom Cowie et al [50], 2017 Good (score: 21/28, 75%) 112,993 â¢ 50,571/QALY 3 5 y United States Schmier et al [51], 2016 Good (score: 21/28, 75%) 172,712 â¢ 82,282/QALY 3 Lifetime United States Sandhu et al [52], 2016 Good (score: 23/28, 82%) 56,496 â¢ 13,855/QALY 3 5 y United States Martinson et al [53], 2017 RCT based Good (score: 21/28, 75%) 91,300 â¢ 56,333/QALY 3.5 Lifetime Poland Niewada et al [54], 2021 Moderate (score: 16/28, 57%) ----Italy CalÃ² et al [55], 2013 Moderate (score: 20/28, 71%) 62,166 â¢ Intervention dominant --Italy Zanaboni et al [56], 2013 Mobile apps and wearables (n=3) Model based Good (score: 21/28, 75%) 49,949 â¢ 4380/QALY 3 10 y or until death, whichever occurred first Hong Kong, Special administrative region, China Jiang et al [47], 2021 Good (score: 25/28, 89%) 40,119 â¢ 7127/QALY 1.5 25 y Canada Boodoo et al [48], 2020 Good (score: 21/28, 75%) -â¢ 16,064/QALY 3 -Spain Cano Martin et al [49], 2014 Videoconferencing system (n=1) RCT based Quality of reporting (CHEERS d checklist) WTP b threshold (in 2023 US $/QALY c ) ICER a (in 2023 US $) Discount rate (%) Time horizon Country Study Good (score: 24/28, 86%) 40,000 â¢ -3325/QALY (savings) --Australia Hwang et al [57], 2018 a ICER: incremental cost-effectiveness ratio.</s><s xml:id="_A2pP8u2">b WTP: willingness-to-pay.</s><s xml:id="_BYvNmPP">c QALY: quality-adjusted life year.</s><s xml:id="_DBZ8Sb4">d CHEERS: Consolidated Health Economic Evaluation Reporting Standards.</s><s xml:id="_5JkkMPC">e LY: life-year.</s><s xml:id="_M3ZYQR8">f SoC: standard of care.</s><s xml:id="_gQwz4VY">g HTM: home telemonitoring.</s><s xml:id="_P4Xr8Nq">h DA: diagnostic algorithm.</s><s xml:id="_bzqUb3n">i RCT: randomized controlled trial.</s><s xml:id="_GCnsnzR">j RCT-based evaluation extended with a decision tree model (combination).</s><s xml:id="_pkZMy8q">k Not stated.</s><s xml:id="_b4EcXWp">l N/A: not applicable.</s><s xml:id="_z7fNdND">m UC: usual care.</s><s xml:id="_MA36EHK">n NTS: nurse telephone support.</s><s xml:id="_Nkc6UNU">o PHS: public health care system.</s><s xml:id="_sqbxHmS">J Med Internet Res 2024 | vol.</s><s xml:id="_H5hcQdf">26 | e53500 | p. 9 <ref type="url" target="https://www.jmir.org/2024/1/e53500">https://www.jmir.org/2024/1/e53500</ref></s><s xml:id="_yEtvUrV">(page number not for citation purposes) No study 1</s></p><p xml:id="_VYNybUJ"><s xml:id="_Wmyg8Ms">a Digital health intervention has lower cost or lower effectiveness than the comparator.</s><s xml:id="_JUuPKjE">b 0: digital health intervention has the same cost and same effectiveness as the comparator.</s><s xml:id="_ezZsrWK">c 1: digital health intervention has a higher cost or higher effectiveness than the comparator.</s><s xml:id="_KTcSGAR">e SoC: standard of care (as defined by the European Society of Cardiology and the American Heart Association, American College of Cardiology, and Heart Failure Society of America, it is the standard multidisciplinary management program, which includes regular planned follow-up for the purpose of safety and optimal drug dosing [standard of care with or without drug or exercise prescription], early detection of decompensation, and impact on disease progression that requires modification of the intervention or treatment regimen).</s><s xml:id="_5yD6x5M">o HL: Health Lines.</s></p><p xml:id="_GnpSnwS"><s xml:id="_CkvWr4R">p HF: heart failure.</s></p><p xml:id="_bPheyz8"><s xml:id="_XBMFDXW">q Implantable usual care described as patients with the device implanted but where the data were not used to guide management for remote monitoring.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_QF3DpST">Noninvasive Remote Monitoring Devices</head><p xml:id="_7P77X5S"><s xml:id="_RYHEkGE">Noninvasive remote monitoring devices (n=9) assessed for cost-effectiveness included HTM using medical devices and digital tablets.</s><s xml:id="_WPn3d9S">These devices enable the monitoring of a patient's vital parameters at home, including weight, blood pressure, heart rate, and heart rhythm.</s><s xml:id="_YC2qzXW">These devices enable the transmission of physiological data to the health care team, allowing for early detection of deterioration in patients with HF <ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref>.</s><s xml:id="_5DsFzPh">The prompt sending of these data to health care professionals for assessment facilitates the timely identification of significant changes and enables early interventions <ref type="bibr" target="#b36">[37,</ref><ref type="bibr" target="#b37">38]</ref>.</s><s xml:id="_NqNTjrh">Early interventions help prevent complications and enable patients to avoid emergency admissions, improving patient outcomes <ref type="bibr" target="#b30">[31,</ref><ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b38">39]</ref>.</s></p><p xml:id="_3mtcTc3"><s xml:id="_uZrtjE8">Most of the economic evaluations (7/9, 78%) of noninvasive remote monitoring devices were compared to SoC <ref type="bibr" target="#b18">[19,</ref><ref type="bibr" target="#b19">20]</ref> as defined in the international guidelines <ref type="bibr" target="#b30">[31,</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b37">38,</ref><ref type="bibr" target="#b38">39]</ref>.</s><s xml:id="_pHDrrMF">Although the definitions of SoC are similar, some of the studies (2/9, 22%) provided additional details regarding the follow-up procedures, such as SoC with follow-up once a week <ref type="bibr" target="#b35">[36]</ref> or 4 preplanned outpatient clinic visits <ref type="bibr" target="#b36">[37]</ref>.</s><s xml:id="_KX4DU8u">Among the 9 studies, 4 (44%) used Markov models <ref type="bibr" target="#b30">[31,</ref><ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b33">34,</ref><ref type="bibr" target="#b34">35]</ref>, 1 (11%) used a patient-level discrete-event simulation model <ref type="bibr" target="#b32">[33]</ref>, and 4 (44%) were trial based <ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref>.</s><s xml:id="_g24JHZD">Some of the economic evaluations (4/9, 44%) showed that the implementation of noninvasive remote monitoring devices requires extra costs, mainly regarding the cost of HTM for HF management <ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref>.</s><s xml:id="_ZsJwJrD">Nonetheless, the use of this technology was also accompanied by improved outcomes, such as improved HRQoL <ref type="bibr" target="#b30">[31,</ref><ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b33">34,</ref><ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref>.</s><s xml:id="_WYkY4hH">Although the majority of the results suggested that DHIs were cost-effective, the findings were conflicting.</s><s xml:id="_43eSDZQ">Although most of the studies (7/9, 78%) indicated that noninvasive remote monitoring devices for managing patients with HF were generally cost-effective <ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref>, 22% (2/9) found dissimilar results: of these 2 studies, 1 (50%) conducted from the UK health care perspective reported that the incremental cost per QALY gained for HTM using noninvasive remote monitoring devices exceeded the acceptable willingness-to-pay (WTP) thresholds <ref type="bibr" target="#b34">[35]</ref>, while 1 (50%) conducted in Germany concluded that remote monitoring had higher costs and worse outcomes than SoC and was therefore not an efficient option <ref type="bibr" target="#b35">[36]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_9UQ3u2Y">Telephone Support</head><p xml:id="_vg4gxxu"><s xml:id="_w63dX4w">Structured telephone support (n=7), defined in the included studies, refers to the provision of HTM through self-care support or management by health care professionals, such as nurses, through regular telephone calls, typically on a monthly basis <ref type="bibr" target="#b41">[42,</ref><ref type="bibr" target="#b42">43,</ref><ref type="bibr" target="#b44">45,</ref><ref type="bibr" target="#b45">46]</ref>.</s><s xml:id="_2yRXum7">Of the 7 economic evaluations that used telephone support, 6 (86%) were based on RCTs <ref type="bibr" target="#b40">[41]</ref><ref type="bibr" target="#b41">[42]</ref><ref type="bibr" target="#b42">[43]</ref><ref type="bibr" target="#b43">[44]</ref><ref type="bibr" target="#b44">[45]</ref><ref type="bibr" target="#b45">[46]</ref>, and 1 (14%) was model based <ref type="bibr" target="#b39">[40]</ref>.</s><s xml:id="_ewwEfck">The primary objective of telephone support includes assessing symptoms, reviewing current medications, and providing timely feedback to both physicians and patients <ref type="bibr" target="#b41">[42]</ref>.</s><s xml:id="_ekMun2x">The length of the intervention ranged from 4 to 30 months.</s><s xml:id="_CVZEQK8">The extra costs associated with the telephone support intervention compared to SoC included the costs of telephone calls and specialist follow-up visits.</s><s xml:id="_PFz6q2c">The outcomes measured included hospital readmission prevented over 24 weeks <ref type="bibr" target="#b40">[41]</ref> and HRQoL <ref type="bibr" target="#b39">[40,</ref><ref type="bibr" target="#b41">42,</ref><ref type="bibr" target="#b43">[44]</ref><ref type="bibr" target="#b44">[45]</ref><ref type="bibr" target="#b45">[46]</ref>.</s><s xml:id="_mgzkZqT">The comparator SoC adhered to the definition provided in the guidelines <ref type="bibr" target="#b18">[19,</ref><ref type="bibr" target="#b19">20]</ref>, or it involved routine ambulatory evaluations in 3 to 4 months <ref type="bibr" target="#b44">[45]</ref>.</s><s xml:id="_EVyKHSN">Overall, the results showed that telephone support was cost-effective compared to SoC (6/7, 86%) <ref type="bibr" target="#b39">[40]</ref><ref type="bibr" target="#b40">[41]</ref><ref type="bibr" target="#b41">[42]</ref><ref type="bibr" target="#b42">[43]</ref><ref type="bibr" target="#b44">45,</ref><ref type="bibr" target="#b45">46]</ref>.</s><s xml:id="_4qmhprq">However, 1 (14%) of the 7 studies concluded that telephone support was not cost-effective in the United States because it surpassed the acceptable cost-effectiveness threshold as higher total costs in the intervention group were combined with a relatively small difference in health outcomes compared to the SoC group (ie, usual management by physicians) <ref type="bibr" target="#b43">[44]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_JE5Xze4">Remote Monitoring Follow-Up in Patients With Implantable Medical Devices</head><p xml:id="_cCe5Frh"><s xml:id="_n6gk3YC">Of the 27 studies, 7 (26%) assessed the cost-effectiveness of remote monitoring follow-up in patients with implantable medical devices.</s><s xml:id="_VFUHzTA">Of these 7 studies, 3 (43%) were trial based <ref type="bibr" target="#b53">[54]</ref><ref type="bibr" target="#b54">[55]</ref><ref type="bibr" target="#b55">[56]</ref>, and 4 (57%) were model based <ref type="bibr" target="#b49">[50]</ref><ref type="bibr" target="#b50">[51]</ref><ref type="bibr" target="#b51">[52]</ref><ref type="bibr" target="#b52">[53]</ref>.</s><s xml:id="_dD62WpN">The interventions included remote monitoring follow-up for patients using cardiac implantable electronic devices, which are used to manage conditions such as bradycardia and HF to prevent sudden cardiac death <ref type="bibr" target="#b57">[58]</ref>.</s><s xml:id="_d4jWgVC">The 4 model-based studies <ref type="bibr" target="#b49">[50]</ref><ref type="bibr" target="#b50">[51]</ref><ref type="bibr" target="#b51">[52]</ref><ref type="bibr" target="#b52">[53]</ref> assessed the same device, that is, the CardioMEMS implantable hemodynamic sensor, which provides remote real-time pressure measurements from the pulmonary artery <ref type="bibr" target="#b58">[59]</ref>.</s><s xml:id="_Kh3725n">This wireless sensor transmits hemodynamic information to the patient database website, enabling health care professionals to promptly make decisions regarding treatment initiation and adjustments when changes in pulmonary artery pressure and signs of HF are detected.</s><s xml:id="_C4hQx2q">The comparator comprised usual care described as patients with the device implanted but where the data were not used to guide management for remote monitoring (implantable usual care) <ref type="bibr" target="#b49">[50]</ref><ref type="bibr" target="#b50">[51]</ref><ref type="bibr" target="#b51">[52]</ref><ref type="bibr" target="#b52">[53]</ref>.</s><s xml:id="_9X6wX3z">The 3 trial-based studies focused on remote monitoring follow-up with patients having cardiac implantable electronic devices compared to conventional follow-up <ref type="bibr" target="#b53">[54]</ref><ref type="bibr" target="#b54">[55]</ref><ref type="bibr" target="#b55">[56]</ref>.</s><s xml:id="_XE4qJuA">The comparator included patients who typically attended regular follow-up visits at the clinic based on a predetermined calendar schedule <ref type="bibr" target="#b53">[54]</ref>.</s><s xml:id="_BKkB2pF">Furthermore, 2 (67%) of these 3 studies provided specific details of their study settings: of these 2 studies, 1 (50%) described outpatient clinic visits every 3 to 6 months according to the standard schedule at the participating center <ref type="bibr" target="#b54">[55]</ref>, while 1 (50%) had scheduled in-office visits at 4, 8, 12, and 16 months <ref type="bibr" target="#b55">[56]</ref>.</s><s xml:id="_JYvbS94">Generally, costs associated with implantable devices followed by remote monitoring consist of the cost of visits to physicians and nurses and fees for the remote monitoring service, as well as the costs of the transmitter device, battery replacement, and cardiovascular treatment.</s></p><p xml:id="_ve7HmkX"><s xml:id="_a2r5cAg">All studies indicated that implantable medical devices, especially for patients with severe HF (eg, New York Heart Association class III and class IV), were considered cost-effective <ref type="bibr" target="#b49">[50]</ref><ref type="bibr" target="#b50">[51]</ref><ref type="bibr" target="#b51">[52]</ref><ref type="bibr" target="#b52">[53]</ref><ref type="bibr" target="#b53">[54]</ref><ref type="bibr" target="#b54">[55]</ref><ref type="bibr" target="#b55">[56]</ref>.</s><s xml:id="_cYWSjWr">In Italy, they were even deemed a dominant strategy, leading to improved health outcomes while incurring lower total costs <ref type="bibr" target="#b55">[56]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_2EzpE6c">Mobile Apps and Wearables</head><p xml:id="_9gW5KzJ"><s xml:id="_aAGNWfA">Of the 27 studies, 3 (11%) assessed the cost-effectiveness of providing HTM through expert counseling services via mobile apps <ref type="bibr" target="#b46">[47]</ref><ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b48">[49]</ref>.</s><s xml:id="_BQsCN7d">The mobile apps provide a platform for patients to self-manage their heart condition <ref type="bibr" target="#b47">[48]</ref>.</s><s xml:id="_MXQS4Cc">The information section in the app contains a patient manual and medical information <ref type="bibr" target="#b48">[49]</ref>, while a separate section enables users to track their activity (physical activity and food consumption) and record health measurements such as vital signs <ref type="bibr" target="#b46">[47]</ref><ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b48">[49]</ref>.</s><s xml:id="_nX79uPB">In addition, the app includes a medication registry feature that allows patients to set reminders for medication administration times <ref type="bibr" target="#b48">[49]</ref>.</s><s xml:id="_kGsnBNY">The features of mobile apps in the included studies were similar, that is, they included a feature that allowed the patient to transmit vital measurements (heart rate, blood pressure, and weight) daily to the HF management team, followed by interpretation by experts and categorization of the patient's condition as well as feedback regarding the patient's condition such as medication dosage adjustments or recommendations for the patients to visit the emergency department.</s><s xml:id="_hgVqdu5">Reminders for patients to enter data were in the form of alarms <ref type="bibr" target="#b47">[48,</ref><ref type="bibr" target="#b48">49]</ref>.</s><s xml:id="_JChgYfD">All studies in this group conducted a model-based economic evaluation that compared add-on mobile apps to SoC <ref type="bibr" target="#b18">[19,</ref><ref type="bibr" target="#b19">20]</ref>.</s><s xml:id="_8YeGmcz">The additional costs of mobile app technology rely mainly on monitoring and treatment, with outcomes captured as HRQoL.</s><s xml:id="_Va5Xse3">All included studies indicated that the mobile apps were cost-effective (ie, below the WTP thresholds in each setting) <ref type="bibr" target="#b46">[47]</ref><ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b48">[49]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_j4hnskA">Videoconferencing System</head><p xml:id="_7Est5M2"><s xml:id="_NahUM2E">Only 1 (4%) of the 27 studies assessed the cost-effectiveness of providing specialist consultation services to remote patients with HF via a videoconferencing system (known as telerehabilitation) <ref type="bibr" target="#b56">[57]</ref>.</s><s xml:id="_p5RQvvr">A web-based commercial videoconferencing platform was used for synchronized audiovisual communication with groups of up to 4 participants <ref type="bibr" target="#b56">[57]</ref>.</s><s xml:id="_ycuusdN">The videoconferencing system equipment included a laptop computer and mobile broadband devices connected to 3G wireless broadband internet; in addition, the participants were provided a finger pulse oximeter, an automatic sphygmomanometer, free weights, and resistance bands <ref type="bibr" target="#b56">[57]</ref>.</s><s xml:id="_a7Rm8qa">In telerehabilitation, a physiotherapist supervised each training session, and a physiotherapist and a nurse led the information session <ref type="bibr" target="#b56">[57]</ref>.</s><s xml:id="_8W3ZA34">The results suggested no significant differences in QALYs, but the health care costs per participant were significantly lower in the telerehabilitation group, with a savings of US $3325 per QALY <ref type="bibr" target="#b56">[57]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_TynBNvV">Quality of Reporting</head><p xml:id="_htHSkJv"><s xml:id="_mnfKTvQ">Of the 27 studies, 20 (74%) were rated good <ref type="bibr" target="#b31">[32,</ref><ref type="bibr" target="#b32">33,</ref><ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b39">[40]</ref><ref type="bibr" target="#b40">[41]</ref><ref type="bibr" target="#b41">[42]</ref><ref type="bibr" target="#b42">[43]</ref><ref type="bibr" target="#b43">[44]</ref><ref type="bibr" target="#b45">[46]</ref><ref type="bibr" target="#b46">[47]</ref><ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b48">[49]</ref><ref type="bibr" target="#b49">[50]</ref><ref type="bibr" target="#b50">[51]</ref><ref type="bibr" target="#b51">[52]</ref><ref type="bibr" target="#b52">[53]</ref><ref type="bibr" target="#b53">[54]</ref><ref type="bibr" target="#b56">57]</ref>, 6 (22%) were rated moderate <ref type="bibr" target="#b33">[34,</ref><ref type="bibr" target="#b35">36,</ref><ref type="bibr" target="#b36">37,</ref><ref type="bibr" target="#b44">45,</ref><ref type="bibr" target="#b54">55,</ref><ref type="bibr" target="#b55">56]</ref>, and 1 (4%) was rated excellent <ref type="bibr" target="#b30">[31]</ref>.</s><s xml:id="_rkBU8nj">Table <ref type="table" target="#tab_3">2</ref> shows the percentage of items fulfilled by each study according to the CHEERS checklist.</s></p><p xml:id="_m989KEe"><s xml:id="_5fC5m9c">The degree of adherence to the reporting criteria in the CHEERS checklist varied across the sections.</s><s xml:id="_QGyjVEK">Some items, such as background, intervention and comparator, study findings, generalizability, and funding, were adequately reported by all studies.</s><s xml:id="_WBFeHx8">The CHEERS checklist emphasizes the inclusion of essential and specific elements in the methods section, and nearly all studies included in this analysis comply with the checklist requirements, for example, the measurement and valuation of resources and costs (26/27, 96%) <ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref>, perspective (26/27, 96%) <ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b39">[40]</ref><ref type="bibr" target="#b40">[41]</ref><ref type="bibr" target="#b41">[42]</ref><ref type="bibr" target="#b42">[43]</ref><ref type="bibr" target="#b43">[44]</ref><ref type="bibr" target="#b44">[45]</ref><ref type="bibr" target="#b45">[46]</ref><ref type="bibr" target="#b46">[47]</ref><ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b48">[49]</ref><ref type="bibr" target="#b50">[51]</ref><ref type="bibr" target="#b51">[52]</ref><ref type="bibr" target="#b52">[53]</ref><ref type="bibr" target="#b53">[54]</ref><ref type="bibr" target="#b54">[55]</ref><ref type="bibr" target="#b55">[56]</ref><ref type="bibr" target="#b56">[57]</ref>, setting and location (25/27, 93%) <ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b39">[40]</ref><ref type="bibr" target="#b40">[41]</ref><ref type="bibr" target="#b41">[42]</ref><ref type="bibr" target="#b42">[43]</ref><ref type="bibr" target="#b44">[45]</ref><ref type="bibr" target="#b45">[46]</ref><ref type="bibr" target="#b46">[47]</ref><ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b48">[49]</ref><ref type="bibr" target="#b49">[50]</ref><ref type="bibr" target="#b51">[52]</ref><ref type="bibr" target="#b52">[53]</ref><ref type="bibr" target="#b53">[54]</ref><ref type="bibr" target="#b54">[55]</ref><ref type="bibr" target="#b55">[56]</ref><ref type="bibr" target="#b56">[57]</ref>, the measurement of outcomes (25/27, 93%) <ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b39">[40]</ref><ref type="bibr" target="#b40">[41]</ref><ref type="bibr" target="#b41">[42]</ref><ref type="bibr" target="#b42">[43]</ref><ref type="bibr" target="#b43">[44]</ref><ref type="bibr" target="#b44">[45]</ref><ref type="bibr" target="#b45">[46]</ref><ref type="bibr" target="#b46">[47]</ref><ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b49">[50]</ref><ref type="bibr" target="#b50">[51]</ref><ref type="bibr" target="#b51">[52]</ref><ref type="bibr" target="#b52">[53]</ref><ref type="bibr" target="#b53">[54]</ref><ref type="bibr" target="#b54">[55]</ref><ref type="bibr" target="#b55">[56]</ref><ref type="bibr" target="#b56">[57]</ref>, and the selection of outcomes (24/27, 89%) <ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b39">[40]</ref><ref type="bibr" target="#b40">[41]</ref><ref type="bibr" target="#b41">[42]</ref><ref type="bibr" target="#b42">[43]</ref><ref type="bibr" target="#b44">[45]</ref><ref type="bibr" target="#b45">[46]</ref><ref type="bibr" target="#b46">[47]</ref><ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b49">[50]</ref><ref type="bibr" target="#b50">[51]</ref><ref type="bibr" target="#b51">[52]</ref><ref type="bibr" target="#b52">[53]</ref><ref type="bibr" target="#b53">[54]</ref><ref type="bibr" target="#b55">56,</ref><ref type="bibr" target="#b56">57]</ref>.</s><s xml:id="_XSNrngt">However, there were certain items in the methods section that were reported less often; for instance, the approach to engagement with patients and other individuals affected by the study was only addressed in 2 (7%) of the 27 studies <ref type="bibr" target="#b30">[31,</ref><ref type="bibr" target="#b38">39]</ref>, and the impact of such engagement was discussed in only 1 (4%) of the 27 studies <ref type="bibr" target="#b30">[31]</ref>.</s><s xml:id="_x8TSS3X">This limited reporting may be due to the fact that these items apply specifically to evaluation from trial-based data.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_4Ymh5ak">Discussion</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_sAYUHrb">Principal Findings</head><p xml:id="_ytRnSPW"><s xml:id="_DjagHWb">This systematic review comprehensively searched for, and summarized, the economic evaluations of various DHI devices used for managing patients with HF.</s><s xml:id="_Ud5UVnv">In this review, we identified 27 studies, including both RCT-and model-based economic evaluations.</s><s xml:id="_FJgh6Hs">The findings indicated that the types of DHI devices that were most frequently subjected to an economic evaluation were noninvasive remote monitoring devices (eg, HTM using digital tablets) and medical devices that enabled the transmission of physiological data, followed by telephone support, mobile apps and wearables, remote monitoring follow-up in patients with implantable medical devices (eg, implantable cardioverter defibrillators), and a videoconferencing system.</s><s xml:id="_m8K8bDs">The 27 studies, except for 2 (7%) from Brazil, were conducted in HICs, highlighting the lack of such assessment in LMICs.</s><s xml:id="_n6TP3fU">Despite the diverse range of devices and technologies used for delivering the interventions, the overall results demonstrated that DHIs are potentially more cost-effective than non-DHI alternatives or SoC.</s></p><p xml:id="_caj6G4W"><s xml:id="_aqbWDnk">Our findings suggest that HTM via mobile apps and wearables <ref type="bibr" target="#b46">[47]</ref><ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b48">[49]</ref>,</s></p><p xml:id="_HzbQHZY"><s xml:id="_2ByZZse">home-based telerehabilitation using a videoconferencing system <ref type="bibr" target="#b56">[57]</ref>, and remote monitoring follow-up in patients with implantable medical devices <ref type="bibr" target="#b49">[50,</ref><ref type="bibr" target="#b50">51,</ref><ref type="bibr" target="#b53">[54]</ref><ref type="bibr" target="#b54">[55]</ref><ref type="bibr" target="#b55">[56]</ref> may be potentially dominant options in managing HF, with less total cost and higher effectiveness.</s><s xml:id="_AZv5t59">The included studies demonstrate that remote monitoring follow-up in patients with implantable devices resulted in increased coverage of patient services, improved HRQoL <ref type="bibr" target="#b49">[50]</ref><ref type="bibr" target="#b50">[51]</ref><ref type="bibr" target="#b51">[52]</ref><ref type="bibr" target="#b52">[53]</ref><ref type="bibr" target="#b53">[54]</ref><ref type="bibr" target="#b55">56]</ref>, reduced years of life lost, and potentially reduced cost <ref type="bibr" target="#b54">[55,</ref><ref type="bibr" target="#b55">56]</ref>.</s><s xml:id="_D3XVf2A">Of the 7 studies in this category, 4 (57%) focused on the economic evaluation of remote monitoring of intracardiac and pulmonary artery pressures in patients with HF via implantable hemodynamic monitoring devices in the United States and the United Kingdom <ref type="bibr" target="#b49">[50]</ref><ref type="bibr" target="#b50">[51]</ref><ref type="bibr" target="#b51">[52]</ref><ref type="bibr" target="#b52">[53]</ref>.</s><s xml:id="_ZH5qsFq">The ICERs ranged from US $13,855 to US $82,782, and all were estimated to be below the respective WTP thresholds in each setting and deemed cost-effective.</s><s xml:id="_UE92rNv">The subgroup analysis estimated that such a device might be more beneficial in terms of cost-effectiveness in patients with both types of HF: those with reduced ejection fraction and those with preserved ejection fraction <ref type="bibr" target="#b51">[52]</ref>.</s><s xml:id="_H57jKGy">This finding aligns with the updated guidelines recommending the consideration of monitoring pulmonary artery pressures using a wireless hemodynamic monitoring system, particularly for patients with symptoms of HF, to enhance clinical outcomes <ref type="bibr" target="#b19">[20]</ref>.</s></p><p xml:id="_TMcMqAg"><s xml:id="_ZxjgPeS">Nevertheless, the evidence is limited, especially in mobile apps and wearables as well as home-based telerehabilitation.</s><s xml:id="_p3jAK2G">While mobile apps and wearables are occasionally marketed directly to consumers for health and lifestyle maintenance, of the 27 studies, 3 (11%) focused on assessing HTM through HF-specific apps.</s><s xml:id="_KVNQdQ4">The limited evidence and lack of clear app standards pose challenges for decision-makers to make recommendations, although the understanding of the importance of assessment and regulation regarding these DHIs is currently growing.</s><s xml:id="_p2GpnFU">All comparators (3/3, 100%) in these interventions consisted of SoC, as defined in the guidelines <ref type="bibr" target="#b18">[19,</ref><ref type="bibr" target="#b19">20]</ref>, which improves the generalizability of the findings.</s><s xml:id="_4X3NyKp">Furthermore, most base-case findings concerning HTM via noninvasive remote monitoring devices and telephone support indicate that HTM is more costly but more effective than conventional SoC comparators.</s><s xml:id="_uZwjgzf">The observed ICERs ranged from US $8020 <ref type="bibr" target="#b38">[39]</ref> to US $106,837 <ref type="bibr" target="#b33">[34]</ref> for noninvasive remote monitoring devices and from US $3331 <ref type="bibr" target="#b41">[42]</ref> to US $212,586 <ref type="bibr" target="#b43">[44]</ref> for telephone support, both per QALYs gained.</s><s xml:id="_Y225aun">While most of the studies (9/16, 56%) concluded that the ICERs remained below the WTP thresholds in their respective settings, thus making them cost-effective, certain countries with lower WTP thresholds yielded different findings <ref type="bibr">(3/16, 19%)</ref>, resulting in conflicting conclusions regarding the cost-effectiveness of these interventions.</s><s xml:id="_NpnWrhh">The WTP thresholds identified in the studies involving noninvasive remote monitoring devices ranged from US $15,372 <ref type="bibr" target="#b30">[31]</ref> to US $105,146 <ref type="bibr" target="#b32">[33]</ref>, and all were derived from studies conducted in HICs.</s><s xml:id="_qj9PpME">Hence, it is crucial to be cautious when applying these results in wider settings, especially in LMICs with relatively lower WTP-per-QALY threshold levels, because what may be considered a cost-effective intervention in settings with higher WTP thresholds could yield different outcomes in countries with lower WTP thresholds.</s><s xml:id="_yJQM2bz">Other included studies (4/16, 25%) indicated that HTM via noninvasive remote monitoring devices or telephone support can be a dominant strategy <ref type="bibr" target="#b37">[38,</ref><ref type="bibr" target="#b38">39,</ref><ref type="bibr" target="#b44">45,</ref><ref type="bibr" target="#b45">46]</ref>, with a lower total cost and higher effectiveness than SoC.</s><s xml:id="_QDUAMxs">The cost savings observed in these studies were primarily attributed to reduced hospitalization expenses, especially with regard to the noninvasive devices.</s><s xml:id="_Sf9EZ2m">This aligns with the primary objective of intervention in HF management because lowering cardiovascular-related hospitalizations and all-cause mortality represents an important clinical end point in most trials assessing HF treatments <ref type="bibr" target="#b59">[60]</ref>.</s><s xml:id="_kJ7TDMf">The effectiveness of HTM <ref type="bibr" target="#b31">[32]</ref> and the cost of HF management <ref type="bibr" target="#b30">[31]</ref> are identified as some of the most sensitive parameters that could influence the outcomes of the base-case analysis in model-based studies.</s><s xml:id="_f45ShbV">Moreover, input parameters associated with hospitalization <ref type="bibr" target="#b32">[33,</ref><ref type="bibr" target="#b33">34,</ref><ref type="bibr" target="#b40">41]</ref> and the cost of the intervention <ref type="bibr" target="#b40">[41,</ref><ref type="bibr" target="#b43">44,</ref><ref type="bibr" target="#b44">45]</ref> are among the most sensitive variables in RCT-based studies.</s></p><p xml:id="_ZuRqxW4"><s xml:id="_zut4FqX">In the analysis using noninvasive remote monitoring devices, the distribution of model-based and RCT-based studies is comparable and primarily reflects current updates because the majority (7/9, 78%) were published recently.</s><s xml:id="_WWarhYn">In the case of telephone support, the economic evaluations are predominantly based on RCTs, with the most recent study dating back to 2018 <ref type="bibr" target="#b40">[41,</ref><ref type="bibr" target="#b44">45,</ref><ref type="bibr" target="#b45">46]</ref>.</s><s xml:id="_gCrwX5V">The international guidelines from both the European Society of Cardiology and the American College of Cardiology written in the era before the COVID-19 pandemic do not recommend routine use of remote monitoring or HTM <ref type="bibr" target="#b60">[61,</ref><ref type="bibr" target="#b61">62]</ref>.</s><s xml:id="_5qngfqT">However, during and after the pandemic, the updated version of guidelines for the treatment and management of HF highlights the potential benefits of continuous monitoring of clinical parameters and optimizing care.</s><s xml:id="_wajjpZ4">Despite inconsistencies in its comparative effectiveness and cost-effectiveness, HTM is mentioned as a possible means of monitoring patients <ref type="bibr" target="#b18">[19,</ref><ref type="bibr" target="#b19">20]</ref>.</s><s xml:id="_BmMgCFd">Previous evidence indicated that systems that focus on a health maintenance approach through continuous optimization by using DHIs such as noninvasive HTM and telephone support seem to reduce the risk for hospitalizations and all-cause mortality and subsequently improve HRQoL <ref type="bibr" target="#b62">[63,</ref><ref type="bibr" target="#b63">64]</ref>.</s></p><p xml:id="_VmSbSaD"><s xml:id="_CyAMhF7">Our findings indicate inconsistencies in the cost-effectiveness of DHIs, which might be attributed to intervention variation.</s><s xml:id="_bjhEKNV">This variation makes it challenging to compare the different DHIs in terms of design, effectiveness, and cost-effectiveness.</s><s xml:id="_kh9uHVP">We stratified the findings by device, which allows a comparison of each technology and provides a better understanding of the cost and effectiveness of adopting DHIs.</s><s xml:id="_3TeqT75">Economic evaluations of DHIs pose unique challenges compared to those of drugs and medical devices, primarily due to their interacting and evolving features.</s><s xml:id="_Hw6YadM">As observed in this review, most published economic evaluations of DHIs adhere to standard methodological recommendations for evaluating health care technologies, such as pharmaceutical drugs and medical devices.</s><s xml:id="_P9Phz2g">However, there is an argument that these methodological assumptions may not fully reflect the distinct nature of DHIs, which are typically complex interventions composed of multiple interacting components.</s><s xml:id="_Bpz3ZXf">Consequently, assessing their cost-effectiveness requires a broader evaluation of costs and effects.</s><s xml:id="_Et3ccGQ">This evaluation should extend beyond using just 1 outcome measure, such as HRQoL, to include nonhealth benefits and costs beyond health care <ref type="bibr" target="#b64">[65]</ref>.</s></p><p xml:id="_TmswRTV"><s xml:id="_BQe2K3J">In this review, we observed that the incorporation of DHIs is generally associated with improved effectiveness, despite incurring higher total costs.</s><s xml:id="_xhEuEU9">Both short-and long-term time horizons were used in the included studies.</s><s xml:id="_6wEp95E">The studies demonstrated improved cost-effectiveness of DHIs with a long-term time horizon (â¥5 y), indicating the importance of considering a sufficient time horizon to assess the impact of the technology on outcomes.</s><s xml:id="_fTPhcSD">Economic evaluations conducted alongside RCTs tend to use a short time horizon, in line with the timeline of the trials.</s><s xml:id="_nQncyKJ">Determining the time horizon in economic evaluations is crucial because it determines the timing of costs and benefits and how long they should be spread out.</s><s xml:id="_vYQk249">When evaluating technology for patients with chronic conditions with long-term potential effects on both cost and health outcomes, assessments with a time horizon of â¤1 year may not consider benefits spread out over extended periods, potentially resulting in an underestimation of its cost-effectiveness.</s><s xml:id="_WSkDmdm">Combining data from RCTs with modeling that allows the projection of costs and effectiveness in the coming years could offer a viable solution to estimate the economic evaluations of DHIs more accurately.</s></p><p xml:id="_3D5TKdm"><s xml:id="_VuKy6Ec">A previous systematic review on HTM or structured telephone support programs for patients with HF suggested that these interventions were considered cost-effective compared to SoC <ref type="bibr" target="#b65">[66]</ref>.</s><s xml:id="_FZyX3mT">Similar to these results, according to the included studies in this review, DHIs are generally more cost-effective than standard postdischarge care for managing HF.</s><s xml:id="_uahfxb2">DHI systems, using infrastructure such as the telephone and the internet, allow patients to access cardiac rehabilitation programs from home and report signs of worsening conditions, regardless of location or the time of day.</s><s xml:id="_ZQWvbxf">Such systems also enable remote patient monitoring, reducing the burden on hospitals and health care resources and potentially leading to overall cost savings <ref type="bibr" target="#b66">[67]</ref>.</s><s xml:id="_FSZSpfC">The widespread availability of internet and telephone access in patients' homes, combined with the ease and affordability of implementing remote monitoring systems in clinical practice, make DHIs a potentially cost-effective option <ref type="bibr" target="#b14">[15]</ref>.</s></p><p xml:id="_UjJ5mDE"><s xml:id="_24ZmR8q">Given the significant clinical and economic burden of HF in LMICs <ref type="bibr" target="#b7">[8]</ref>, the potential implementation of DHIs in these settings is promising.</s><s xml:id="_Eg6YdDG">However, evidence on the cost-effectiveness of DHIs in LMICs is very limited, as observed in this review.</s><s xml:id="_kDXatNy">To ensure successful implementation, there is a need to test the validity and reliability of DHIs, tailoring their function and design to the specific needs of programs in LMICs, thereby minimizing potential implementation challenges <ref type="bibr" target="#b67">[68]</ref>.</s><s xml:id="_vqm7Szv">The transformative potential of digital health in improving health outcomes depends on substantial investment in governance, institutional capacity, and workforce training to navigate the evolving digital landscape of health systems <ref type="bibr" target="#b68">[69]</ref>.</s><s xml:id="_km6rNCq">Comprehensive evidence on the acceptability and cost-effectiveness of DHIs within specific settings in LMICs, including financial considerations, must be integrated into routine health budgets and budgeting processes to assess full-scale sustainability.</s><s xml:id="_tBxrBpN">Consequently, securing sufficient and sustainable financial resources, especially given the financial constraints in LMICs, is crucial.</s><s xml:id="_eufYqB8">Mobilizing additional resources from development partners is essential in this regard.</s><s xml:id="_UqQWAPR">With strategic investments aligned with national digital health strategies, digital health has the potential to enhance care efficiency and cost-effectiveness, ultimately leading to improved health care service delivery <ref type="bibr" target="#b69">[70]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_kRUme47">Strengths and Limitations</head><p xml:id="_sFeyzCR"><s xml:id="_4Cjd2a7">The strength of our systematic review is that we assessed various DHIs-both decision-analytic model-based and trial-based economic evaluations of DHIs in managing HF globally-encompassing HTM, rehabilitation, and remote monitoring follow-up after cardiac device implantation.</s><s xml:id="_zTQVujt">The results of this study may facilitate comparisons and assist policy makers in making informed decisions on how to improve the health outcomes of patients with HF.</s></p><p xml:id="_Qs6SpVq"><s xml:id="_HXq3z7E">Inevitably, our study has some limitations.</s><s xml:id="_3YcxQxk">Due to the variability of the methods, devices, and DHI technologies in the included studies, the comparability of studies is limited.</s><s xml:id="_HXVk3Qx">We try to overcome this limitation by using a narrative approach; thus, the variations in methodology and study design can be observed thoroughly.</s><s xml:id="_H9y2DYZ">It is important to note that nearly all included studies (25/27, 93%) are from HICs, and caution is warranted when generalizing their results, particularly to LMICs, due to differences in health care systems and resource availability.</s><s xml:id="_A7Fbwng">In addition, although we used a broad definition of DHIs that includes genomics for personalized medicine and artificial intelligence, we did not find any studies related to these concepts.</s><s xml:id="_jsRBqEN">This may be attributed to the existing gaps in clinical and cost-effectiveness evidence <ref type="bibr" target="#b70">[71]</ref> when integrating these approaches in the context of HF.</s><s xml:id="_5mKtwvA">Nonetheless, the use of precision medicine, which holds the potential to improve clinical outcomes, represents a promising avenue for the future of precision medicine <ref type="bibr" target="#b71">[72]</ref>.</s><s xml:id="_6dD6SG2">In addition, the search strategy used for this systematic review had some constraints.</s><s xml:id="_4mVh6tM">The search terms were constructed using the population, intervention, comparator, and outcomes method, emphasizing a predefined set of terms related to economic evaluations, HF, and DHIs.</s><s xml:id="_N4eR7cS">It is possible that this approach may have overlooked relevant studies that use different keywords.</s><s xml:id="_tpFUqHD">To mitigate this potential gap, we cross-checked the references of the included economic evaluations.</s><s xml:id="_KMTGCMu">Thus, even if we did overlook any, we anticipate that the number will be minimal.</s><s xml:id="_SEPYp6K">Furthermore, considering the variability in the DHIs, modeling approaches, ICER values, and WTP thresholds, it is crucial to perform economic evaluations customized to the specific setting and country.</s><s xml:id="_mPWWnTh">This is especially relevant for LMICs, where the choice of technology, analytical methods, and models should align with the local context.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_gE5qzeR">Conclusions</head><p xml:id="_rPfWpJY"><s xml:id="_vWhbanY">This review includes 27 studies-model based, RCT based, and combination of both-that focus on economic evaluations of DHIs for patients with HF.</s><s xml:id="_J5eRJRf">The results indicated that noninvasive remote monitoring devices, followed by telephone support, mobile apps and wearables, remote monitoring follow-up in patients with implantable medical devices, and videoconferencing systems are the DHI devices most frequently subjected to economic evaluations in managing HF.</s><s xml:id="_s2Z8R7K">Our main findings suggested that adopting DHIs as part of HF treatment and management, in general, requires extra costs but is accompanied by improved health outcomes as measured by HRQoL, compared to SoC, thus seeming to be cost-effective.</s><s xml:id="_H3R8T6v">However, this depends on each country's WTP thresholds for considering cost-effectiveness.</s><s xml:id="_8XDh6Vu">The majority of the studies (25/27, 93%) are from HICs, and the findings may not be generalizable to LMICs.</s><s xml:id="_AeDTfSY">Improvement in the quality of reporting, especially in the methodology of further economic evaluations, would better inform the cost-and health-related outcomes of incorporating DHIs for patients with HF.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p xml:id="_Muvw3we"><s xml:id="_cPU5VEx">Figure 1.</s><s xml:id="_s3b2X5w">The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart of the study selection process.</s></p></div></figDesc><graphic coords="4,56.69,272.01,481.88,332.63" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><figDesc><div><p xml:id="_yuNtF7s"><s xml:id="_6pmgwDt">d DHI: digital health intervention.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><figDesc><div><p xml:id="_upNeSwV"><s xml:id="_MUaUyNX">f HTM: home telemonitoring.</s><s xml:id="_6378zzu">g Randomized controlled trial based.</s><s xml:id="_UvdCnCH">h SCAD: Suivi Clinique A Domicile (Clinical Follow-Up At Home).</s><s xml:id="_6cjVm2d">i Model based.</s><s xml:id="_Shq9d6h">j STSHM: structured telephone support via human-to-machine.</s><s xml:id="_wvVnVsv">k STSHH: structured telephone support via human-to-human.</s><s xml:id="_gN2KgAz">l DA: diagnostic algorithm.</s><s xml:id="_tnbZjBT">m NYHA: New York Heart Association.n</s><s xml:id="_8d8SftZ">Randomized controlled trial-based evaluation extended with a decision tree model (combination).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><figDesc><div><p xml:id="_3RtfNS2"><s xml:id="_uvFBXAb">r HCTR: hybrid comprehensive telerehabilitation.</s><s xml:id="_xjZpmWh">s DM: disease management.</s><s xml:id="_ZVUKusD">t N/A: not applicable.</s><s xml:id="_Vnp8fd7">u ICD: implantable cardioverter defibrillator.v</s><s xml:id="_8N8z8ps">RPM: remote patient management.w</s><s xml:id="_J3qfDMG">DMP: Disease management program.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 1 .</head><label>1</label><figDesc><div><p xml:id="_yUqDKJ7"><s xml:id="_3kNv7Yd">General characteristics of included studies.</s></p></div></figDesc><table><row><cell>Studies (n=27), n (%)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 2 .</head><label>2</label><figDesc><div><p xml:id="_A33Qpah"><s xml:id="_JZKfHe9">Summary and quality assessment of the included studies.</s></p></div></figDesc><table><row><cell>Study</cell><cell>Country</cell><cell>Time horizon</cell><cell>rate (%) Discount</cell><cell cols="2">ICER a (in 2023 US $)</cell><cell>US $/QALY c ) WTP b thresh-old (in 2023</cell><cell>Quality of re-porting checklist) (CHEERS d</cell></row><row><cell cols="2">Noninvasive remote monitoring devices (n=9)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Model based</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Caillon et al [31], 2022</cell><cell>France</cell><cell>10 y</cell><cell>2.5</cell><cell>â¢ â¢</cell><cell>8456/QALY 5955/LY e</cell><cell>15,372</cell><cell>Excellent (score: 28/28, 100%)</cell></row><row><cell>Thokala et al</cell><cell>United Kingdom</cell><cell>30 y</cell><cell>3.5</cell><cell>â¢</cell><cell>20,715/QALY</cell><cell>34,895</cell><cell>Good (score:</cell></row><row><cell>[32], 2013</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>25/28, 89%)</cell></row><row><cell>Albuquerque de Almeida et al [33], 2022</cell><cell>Netherlands</cell><cell>Lifetime</cell><cell>4</cell><cell>â¢ â¢</cell><cell>SoC f vs HTM g : 45,277/QALY SoC vs HTM+DA h :</cell><cell>105,146</cell><cell>Good (score: 24/28, 86%)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>36,422/QALY</cell><cell></cell><cell></cell></row><row><cell>Jiang et al [34], 2020</cell><cell>United States</cell><cell>35 y</cell><cell>3</cell><cell>â¢ â¢ â¢</cell><cell>40,691/QALY 37,641/QALY 106,837/QALY</cell><cell>53,183</cell><cell>Moderate (score: 21/28, 75%)</cell></row><row><cell>Thokala et al</cell><cell>United Kingdom</cell><cell>Lifetime</cell><cell>3.5</cell><cell>â¢</cell><cell>72,028/QALY</cell><cell>29,904</cell><cell>Good (score:</cell></row><row><cell>[35], 2020</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>22/28, 79%)</cell></row><row><cell>RCT i,j based</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>2022 VÃ¶ller et al [36],</cell><cell>Germany</cell><cell>1 y</cell><cell>-k</cell><cell>â¢</cell><cell>-1474/d</cell><cell>-</cell><cell>Moderate (score: 20/28,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>71%)</cell></row><row><cell>2013 Boyne et al [37],</cell><cell>Netherlands</cell><cell>-</cell><cell>N/A l</cell><cell>â¢</cell><cell>59,822/QALY</cell><cell>74,182</cell><cell>Moderate (score: 19/28,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>68%)</cell></row><row><cell>Sydow et al [38],</cell><cell>Germany</cell><cell>-</cell><cell>-</cell><cell>â¢</cell><cell>Dominant (cost sav-</cell><cell>-</cell><cell>Good (score:</cell></row><row><cell>2021</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>ings: 2358 per patient</cell><cell></cell><cell>21/28, 75%)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>year)</cell><cell></cell><cell></cell></row><row><cell>Vestergaard et al</cell><cell>Denmark</cell><cell>1 y</cell><cell>4</cell><cell>â¢</cell><cell>8020/QALY</cell><cell>31,064</cell><cell>Good (score:</cell></row><row><cell>[39], 2020</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>25/28, 89%)</cell></row><row><cell>Telephone support (n=7)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Model based</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Grustam et al [40], 2018</cell><cell>Netherlands</cell><cell>20 y</cell><cell>4</cell><cell>â¢</cell><cell>UC m vs HTM: 17,597/QALY</cell><cell>112,811</cell><cell>Good (score: 25/28, 89%)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>â¢</cell><cell>UC vs NTS n :</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>11,661/QALY</cell><cell></cell><cell></cell></row><row><cell>RCT based</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Ruschel et al [41], 2018</cell><cell>Brazil</cell><cell>6 mo</cell><cell>N/A</cell><cell>â¢</cell><cell>PHS o framework: 332 per hospital read-</cell><cell>-</cell><cell>Good (score: 25/28, 89%)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>mission prevented;</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>the private health care</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>system, using a per-</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>spective of private</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>health care system,</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>the intervention was</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>dominant (cost sav-</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>ing)</cell><cell></cell><cell></cell></row><row><cell>Cui et al [42],</cell><cell>Canada</cell><cell>1 y</cell><cell>N/A</cell><cell>â¢</cell><cell>3331/QALY</cell><cell>55,985</cell><cell>Good (score:</cell></row><row><cell>2013</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>24/28, 86%)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 3 .</head><label>3</label><figDesc><div><p xml:id="_Q9vYjFY"><s xml:id="_hsQVa6h">Relative costs, effects, and main outcomes.</s></p></div></figDesc><table><row><cell>Relative</cell><cell cols="2">Relative effect</cell><cell></cell><cell></cell><cell></cell></row><row><cell>cost</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>-a</cell><cell>0 b</cell><cell></cell><cell>1 c</cell><cell></cell></row><row><cell>-</cell><cell>No study</cell><cell>â¢</cell><cell>DHI d is not cost-effective (1/27, 4%) â¢ Noninvasive remote monitoring devices â¢ SoC e +interactive bidirectional HTM f sys-tem (Motiva) vs SoC and patient diary to</cell><cell>â¢</cell><cell cols="2">DHI is cost-effective (15/27, 56%) â¢ Noninvasive remote monitoring devices â¢ SCAD h , home-based interactive telemonitoring service vs standard hospital-based care [31] i</cell></row><row><cell></cell><cell></cell><cell></cell><cell>document health issues once a week [36] g</cell><cell></cell><cell></cell><cell>â¢</cell><cell>STSHM j interface+STSHH k contact+HTM vs SoC</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>[32] i</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>â¢</cell><cell>HTM+DA l vs SoC or HTM+DA vs HTM only [33] i</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>â¢</cell><cell>Universal SoC+HTM for NYHA m class II to IV</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>and class III to IV vs SoC [34] i</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>â¢</cell><cell>Telephone support â¢ HTM or nurse telephone support vs SoC+patient</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>evaluation at the clinic every 4 months [40] i</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>â¢</cell><cell>Nurse-led home visit vs regular visit to outpatient</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>clinic [41] g,n</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>â¢</cell><cell>HL o (nurses and health care providers providing</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>telephone support)+SoC or HL+in-house monitor-</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>ing+SoC vs SoC [42] g</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>â¢</cell><cell>Nurse-led program vs SoC [43] g</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>â¢</cell><cell>Mobile apps and wearables â¢ Add-on HTM via app vs SoC [47] i</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>â¢</cell><cell>HTM system (Medly) via app vs SoC, including</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>specialized multidisciplinary HF p clinics [48]i</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>â¢</cell><cell>Remote monitoring follow-up in patients with im-</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>plantable medical devices</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>â¢</cell><cell>Implantable hemodynamic sensor (CardioMEMS</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>HF system) vs implantable usual care [50] i,q</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>â¢</cell><cell>Implantable hemodynamic sensor (CardioMEMS</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>HF system) vs implantable usual care [51] i,q</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>â¢</cell><cell>Implantable hemodynamic sensor (CardioMEMS</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>HF system) vs implantable usual care [52] i,q</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>â¢</cell><cell>Implantable hemodynamic sensor (CardioMEMS</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>HF system) vs implantable usual care [53] i,q</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>â¢</cell><cell>HCTR r , including telecare, telerehabilitation, and</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>implantable+SoC vs SoC only [54] g</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>â¢</cell><cell cols="2">DHI is not cost-effective (2/27, 7%) Noninvasive remote monitoring devices â¢ â¢ HTM vs SoC [35] i</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>â¢</cell><cell>Telephone support â¢ DM s (telephone support+augmented HTM) vs SoC</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>[44] g</cell></row><row><cell>0</cell><cell>No study</cell><cell>â¢</cell><cell>DHI is cost-effective (1/27, 4%) Noninvasive remote monitoring devices â¢ â¢ HTM vs SoC [37] g</cell><cell>N/A t</cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p xml:id="_HhdJ9s3"><s xml:id="_GwuyEKQ">J Med Internet Res 2024 | vol.</s><s xml:id="_RXwAsHD">26 | e53500 | p. 2 https://www.jmir.org/2024/1/e53500</s><s xml:id="_E6eK64t">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_1"><p xml:id="_W3ytjbV"><s xml:id="_AQVnzcF">J Med Internet Res 2024 | vol.</s><s xml:id="_bf4KSW5">26 | e53500 | p. 3 https://www.jmir.org/2024/1/e53500</s><s xml:id="_xUc8d8N">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_2"><p xml:id="_B9rQffq"><s xml:id="_qxhd6nm">J Med Internet Res 2024 | vol.</s><s xml:id="_d7BfK2E">26 | e53500 | p. 4 https://www.jmir.org/2024/1/e53500</s><s xml:id="_CKvSu3w">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_3"><p xml:id="_yagj4Sp"><s xml:id="_dWqSQqy">J Med Internet Res 2024 | vol.</s><s xml:id="_5FYSfHV">26 | e53500 | p. 5 https://www.jmir.org/2024/1/e53500</s><s xml:id="_UbtDN2Y">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_4"><p xml:id="_adYqXqR"><s xml:id="_vuBnQ92">J Med Internet Res 2024 | vol.</s><s xml:id="_KbQVYpn">26 | e53500 | p. 6 https://www.jmir.org/2024/1/e53500</s><s xml:id="_hz6akaJ">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_5"><p xml:id="_uxq8s85"><s xml:id="_q4XrHPV">J Med Internet Res 2024 | vol.</s><s xml:id="_jebVenG">26 | e53500 | p. 7 https://www.jmir.org/2024/1/e53500</s><s xml:id="_AX6nDdk">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_6"><p xml:id="_8RMCmZW"><s xml:id="_yac3EGq">J Med Internet Res 2024 | vol.</s><s xml:id="_awU4rrG">26 | e53500 | p. 8 https://www.jmir.org/2024/1/e53500</s><s xml:id="_HDsDsBB">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_7"><p xml:id="_dQDzYUy"><s xml:id="_fBGVTxd">J Med Internet Res 2024 | vol.</s><s xml:id="_WSP7QfC">26 | e53500 | p. 10 https://www.jmir.org/2024/1/e53500</s><s xml:id="_ampG5C6">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_8"><p xml:id="_XWauUAW"><s xml:id="_aQ2uV7k">J Med Internet Res 2024 | vol.</s><s xml:id="_dVSzWra">26 | e53500 | p. 11 https://www.jmir.org/2024/1/e53500</s><s xml:id="_MCerKM9">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_9"><p xml:id="_DBxKqd4"><s xml:id="_tRkKWU4">J Med Internet Res 2024 | vol.</s><s xml:id="_Bm7wb3E">26 | e53500 | p. 12 https://www.jmir.org/2024/1/e53500</s><s xml:id="_KW97ZA9">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_10"><p xml:id="_wZ7N9zZ"><s xml:id="_5nPREwx">J Med Internet Res 2024 | vol.</s><s xml:id="_XWxXjBr">26 | e53500 | p. 13 https://www.jmir.org/2024/1/e53500</s><s xml:id="_RwJF29d">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_11"><p xml:id="_dVU3QDw"><s xml:id="_havaTuZ">J Med Internet Res 2024 | vol.</s><s xml:id="_2A7EuXb">26 | e53500 | p. 14 https://www.jmir.org/2024/1/e53500</s><s xml:id="_MB8fTXU">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_12"><p xml:id="_3A98fAj"><s xml:id="_xqcFr85">J Med Internet Res 2024 | vol.</s><s xml:id="_RVGeZsd">26 | e53500 | p. 15 https://www.jmir.org/2024/1/e53500</s><s xml:id="_C3QfD8E">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_13"><p xml:id="_KSmjhcv"><s xml:id="_78aT8zJ">J Med Internet Res 2024 | vol.</s><s xml:id="_nCkARkA">26 | e53500 | p. 16 https://www.jmir.org/2024/1/e53500</s><s xml:id="_Xhu7yyG">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_14"><p xml:id="_nYYk36u"><s xml:id="_NF56WRG">J Med Internet Res 2024 | vol.</s><s xml:id="_fczUnTy">26 | e53500 | p. 17 https://www.jmir.org/2024/1/e53500</s><s xml:id="_EEjvmb4">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_15"><p xml:id="_N5Ak7jN"><s xml:id="_yhY5maB">J Med Internet Res 2024 | vol.</s><s xml:id="_Ekw4t7r">26 | e53500 | p. 18 https://www.jmir.org/2024/1/e53500</s><s xml:id="_tpXbwy7">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_16"><p xml:id="_Ct853E8"><s xml:id="_7qDSukc">J Med Internet Res 2024 | vol.</s><s xml:id="_e4bt37s">26 | e53500 | p. 19 https://www.jmir.org/2024/1/e53500</s><s xml:id="_akVtMDa">(page number not for citation purposes)</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_17"><p xml:id="_jFeabsA"><s xml:id="_GP4hnpa">J Med Internet Res 2024 | vol.</s><s xml:id="_tHq32xC">26 | e53500 | p. 20 https://www.jmir.org/2024/1/e53500</s><s xml:id="_V8ypCgC">(page number not for citation purposes)</s></p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div><head xml:id="_7dmEzGB">Acknowledgments</head><p xml:id="_eF6CJx3"><s xml:id="_SymN5SN">This study was supported by a grant from <rs type="funder">Universitas Padjadjaran, Bandung, Indonesia</rs>.</s></p></div>
			</div>
			<listOrg type="funding">
			</listOrg>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_yxSsGK6">Authors' Contributions</head><p xml:id="_mQZc3B7"><s xml:id="_92jBYxP">This study was conceptualized by NZ, IMP, and KL.</s><s xml:id="_eCDvrgf">The protocol was developed by NZ, DM, and IMP.</s><s xml:id="_wr4ncWp">The search and data extraction were carried out by NZ and DM.</s><s xml:id="_XM7fjjC">Articles were screened for inclusion by NZ, DM, and IMP.</s><s xml:id="_npBrdtt">The analysis was conducted by NZ, DM, and MA.</s><s xml:id="_2S9H8Bz">NZ and JFR were responsible for supervision.</s><s xml:id="_XjRq3tJ">NZ and DM wrote the original draft.</s><s xml:id="_cqyjF9X">All authors were responsible for reviewing and editing the final draft.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Sd9ybnw">Conflicts of Interest</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main" xml:id="_UfYfBHg">Global burden of heart failure: a comprehensive and updated review of epidemiology</title>
		<author>
			<persName><forename type="first">G</forename><surname>Savarese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Becher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Lund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Seferovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Rosano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Coats</surname></persName>
		</author>
		<idno type="DOI">10.1093/cvr/cvac013</idno>
		<idno>Medline: 35150240</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_CUtDr2u">Cardiovasc Res. Jan</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="3272" to="3287" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GM, Coats AJ. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. Jan 18, 2023;118(17):3272-3287. [doi: 10.1093/cvr/cvac013] [Medline: 35150240]</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_tdTEr5S">Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017</title>
		<author>
			<persName><surname>Gbd</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(18)32279-7</idno>
		<idno>Medline: 30496104</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cFybTDD">Lancet. Nov</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">10159</biblScope>
			<biblScope unit="page" from="1789" to="1858" />
			<date type="published" when="2017">2017. 2018</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. Nov 10, 2018;392(10159):1789-1858. [FREE Full text] [doi: 10.1016/S0140-6736(18)32279-7] [Medline: 30496104]</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_DGJbAmp">Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study</title>
		<author>
			<persName><forename type="first">H</forename><surname>Dokainish</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Teo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Roy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">F</forename><surname>Alhabib</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Elsayed</surname></persName>
		</author>
		<idno type="DOI">10.1016/s2214-109x(17)30196-1</idno>
		<idno>Medline: 28476564</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_yjarAC9">Lancet Glob Health</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="665" to="e672" />
			<date type="published" when="2017-07">Jul 2017</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Dokainish H, Teo K, Zhu J, Roy A, AlHabib KF, ElSayed A, et al. Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. Lancet Glob Health. Jul 2017;5(7):e665-e672. [FREE Full text] [doi: 10.1016/S2214-109X(17)30196-1] [Medline: 28476564]</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_bDCy8ug">Quality of life and depressive symptoms in the elderly: a comparison between patients with heart failure and age-and gender-matched community controls</title>
		<author>
			<persName><forename type="first">I</forename><surname>Lesman-Leegte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Jaarsma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Coyne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Hillege</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Van Veldhuisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sanderman</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cardfail.2008.09.006</idno>
		<idno>Medline: 19181289</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_aCZf2Yh">J Card Fail</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="17" to="23" />
			<date type="published" when="2009-02">Feb 2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lesman-Leegte I, Jaarsma T, Coyne JC, Hillege HL, van Veldhuisen DJ, Sanderman R. Quality of life and depressive symptoms in the elderly: a comparison between patients with heart failure and age-and gender-matched community controls. J Card Fail. Feb 2009;15(1):17-23. [doi: 10.1016/j.cardfail.2008.09.006] [Medline: 19181289]</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_jpVEa42">Overview of the socio-economic consequences of heart failure</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">P</forename><surname>Hessel</surname></persName>
		</author>
		<idno type="DOI">10.21037/cdt-20-291</idno>
		<idno>Medline: 33708497</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_swch9wK">Cardiovasc Diagn Ther</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="254" to="262" />
			<date type="published" when="2021-02">Feb 2021</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Hessel FP. Overview of the socio-economic consequences of heart failure. Cardiovasc Diagn Ther. Feb 2021;11(1):254-262. [FREE Full text] [doi: 10.21037/cdt-20-291] [Medline: 33708497]</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_GCK7VZT">Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Heidenreich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Albert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Allen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Bluemke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Butler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">C</forename><surname>Fonarow</surname></persName>
		</author>
		<idno type="DOI">10.1161/hhf.0b013e318291329a</idno>
		<idno>Medline: 23616602</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_tD5vaeS">Circ Heart Fail</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="606" to="619" />
			<date type="published" when="2013-05">May 2013</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. May 2013;6(3):606-619. [FREE Full text] [doi: 10.1161/HHF.0b013e318291329a] [Medline: 23616602]</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_DduxQm4">Heart disease and stroke statistics-2021 update: a report from the American Heart Association</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Virani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Alonso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Aparicio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Benjamin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Bittencourt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Callaway</surname></persName>
		</author>
		<idno type="DOI">10.1161/cir.0000000000000950</idno>
		<idno>Medline: 33501848</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_sMefBh5">Circulation</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="e254" to="e743" />
			<date type="published" when="2021-02-23">Feb 23, 2021</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. Feb 23, 2021;143(8):e254-e743. [FREE Full text] [doi: 10.1161/CIR.0000000000000950] [Medline: 33501848]</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_RAwvMxE">The annual global economic burden of heart failure</title>
		<author>
			<persName><forename type="first">C</forename><surname>Cook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Cole</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Asaria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jabbour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Francis</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ijcard.2013.12.028</idno>
		<idno>Medline: 24398230</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_kPA4Hd2">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">171</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="368" to="376" />
			<date type="published" when="2014-02-15">Feb 15, 2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. Int J Cardiol. Feb 15, 2014;171(3):368-376. [doi: 10.1016/j.ijcard.2013.12.028] [Medline: 24398230]</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_HjRkKsm">The global economic burden of non-communicable diseases</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Bloom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">T</forename><surname>Cafiero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>JanÃ©-Llopis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Abrahams-Gessel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Bloom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fathima</surname></persName>
		</author>
		<ptr target="https://www3.weforum.org/docs/WEF_Harvard_HE_GlobalEconomicBurdenNonCommunicableDiseases_2011.pdf" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_gFVgEBy">World Economic Forum</title>
		<imprint>
			<date type="published" when="2011-09">Sep 2011. 2024-04-12</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bloom DE, Cafiero ET, JanÃ©-Llopis E, Abrahams-Gessel S, Bloom LR, Fathima S, et al. The global economic burden of non-communicable diseases. World Economic Forum. Sep 2011. URL: https://www3.weforum.org/docs/ WEF_Harvard_HE_GlobalEconomicBurdenNonCommunicableDiseases_2011.pdf [accessed 2024-04-12]</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_zdUqn2E">Lifetime analysis of hospitalizations and survival of patients newly admitted with heart failure</title>
		<author>
			<persName><forename type="first">S</forename><surname>Chun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Tu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Wijeysundera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Austin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Levy</surname></persName>
		</author>
		<idno type="DOI">10.1161/circheartfailure.111.964791</idno>
		<idno>Medline: 22556322</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_z9pd9YN">Circ Heart Fail</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="414" to="421" />
			<date type="published" when="2012-07-01">Jul 01. 2012</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Chun S, Tu JV, Wijeysundera HC, Austin PC, Wang X, Levy D, et al. Lifetime analysis of hospitalizations and survival of patients newly admitted with heart failure. Circ Heart Fail. Jul 01, 2012;5(4):414-421. [FREE Full text] [doi: 10.1161/CIRCHEARTFAILURE.111.964791] [Medline: 22556322]</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_c3DVm5Q">Rehospitalization for heart failure: predict or prevent?</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Desai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W</forename><surname>Stevenson</surname></persName>
		</author>
		<idno type="DOI">10.1161/circulationaha.112.125435</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WTe5B54">Circulation</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="501" to="506" />
			<date type="published" when="2012-07">Jul. 2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Desai AS, Stevenson LW. Rehospitalization for heart failure: predict or prevent? Circulation. Jul 24, 2012;126(4):501-506. [doi: 10.1161/circulationaha.112.125435]</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_WajMV7Y">Mobile technology and the digitization of healthcare</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Bhavnani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Narula</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Sengupta</surname></persName>
		</author>
		<idno type="DOI">10.1093/eurheartj/ehv770</idno>
		<idno>Medline: 26873093</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_XbjurWw">Eur Heart J. May</title>
		<imprint>
			<biblScope unit="volume">07</biblScope>
			<biblScope unit="issue">18</biblScope>
			<biblScope unit="page" from="1428" to="1438" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Bhavnani SP, Narula J, Sengupta PP. Mobile technology and the digitization of healthcare. Eur Heart J. May 07, 2016;37(18):1428-1438. [FREE Full text] [doi: 10.1093/eurheartj/ehv770] [Medline: 26873093]</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_VW8Sgsb">Digital health: implications for heart failure management</title>
		<author>
			<persName><forename type="first">A</forename><surname>Singhal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Cowie</surname></persName>
		</author>
		<idno type="DOI">10.15420/cfr.2020.28</idno>
		<idno>Medline: 34035953</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_368gX7a">Card Fail Rev. Mar</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">e08</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Singhal A, Cowie MR. Digital health: implications for heart failure management. Card Fail Rev. Mar 2021;7:e08. [FREE Full text] [doi: 10.15420/cfr.2020.28] [Medline: 34035953]</note>
</biblStruct>

<biblStruct xml:id="b13">
	<monogr>
		<idno type="DOI">10.1016/b978-0-12-817485-2.00019-5</idno>
		<ptr target="https://www.fda.gov/medical-devices/digital-health-center-excellence/what-digital-health" />
		<title level="m" xml:id="_8jEXvbv">What is digital health</title>
		<imprint>
			<publisher>U.S. Food &amp; Drug Administration</publisher>
			<date type="published" when="2020-09-22">Sep 22, 2020. 2023-02-07</date>
		</imprint>
	</monogr>
	<note type="raw_reference">What is digital health? U.S. Food &amp; Drug Administration. Sep 22, 2020. URL: https://www.fda.gov/medical-devices/ digital-health-center-excellence/what-digital-health [accessed 2023-02-07]</note>
</biblStruct>

<biblStruct xml:id="b14">
	<monogr>
		<title level="m" type="main" xml:id="_DBJyGms">mHealth: new horizons for health through mobile technologies: second global survey on eHealth</title>
		<idno type="DOI">10.4258/hir.2012.18.3.231</idno>
		<ptr target="-04-12" />
		<imprint>
			<date type="published" when="2011">2011. 2024</date>
			<publisher>World Health Organization</publisher>
		</imprint>
		<respStmt>
			<orgName>WHO Global Observatory for eHealth</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">WHO Global Observatory for eHealth. mHealth: new horizons for health through mobile technologies: second global survey on eHealth. World Health Organization. 2011. URL: https://apps.who.int/iris/handle/10665/44607 [accessed 2024-04-12]</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main" xml:id="_rNKSbRF">Telemedicine systems and telecommunications</title>
		<author>
			<persName><forename type="first">B</forename><surname>Harnett</surname></persName>
		</author>
		<idno type="DOI">10.1258/135763306775321416</idno>
		<idno>Medline: 16438772</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cXBYqG9">J Telemed Telecare</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="4" to="15" />
			<date type="published" when="2006-06-23">Jun 23. 2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Harnett B. Telemedicine systems and telecommunications. J Telemed Telecare. Jun 23, 2006;12(1):4-15. [doi: 10.1258/135763306775321416] [Medline: 16438772]</note>
</biblStruct>

<biblStruct xml:id="b16">
	<monogr>
		<idno type="DOI">10.2471/b09180</idno>
		<ptr target="https://apps.who.int/iris/handle/10665/311980" />
		<title level="m" xml:id="_77p42fe">WHO guideline: recommendations on digital interventions for health system strengthening: evidence and recommendations</title>
		<imprint>
			<publisher>World Health Organization</publisher>
			<date type="published" when="2019">2019. 2024-04-12</date>
		</imprint>
	</monogr>
	<note type="raw_reference">WHO guideline: recommendations on digital interventions for health system strengthening: evidence and recommendations. World Health Organization. 2019. URL: https://apps.who.int/iris/handle/10665/311980 [accessed 2024-04-12]</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_cWJAsFd">Remote management of heart failure: an overview of telemonitoring technologies</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Brahmbhatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Cowie</surname></persName>
		</author>
		<idno type="DOI">10.15420/cfr.2019.5.3</idno>
		<idno>Medline: 31179018</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_HzWmKsW">Card Fail Rev. May</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="86" to="92" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Brahmbhatt DH, Cowie MR. Remote management of heart failure: an overview of telemonitoring technologies. Card Fail Rev. May 24, 2019;5(2):86-92. [FREE Full text] [doi: 10.15420/cfr.2019.5.3] [Medline: 31179018]</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_bzFzjSd">AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Heidenreich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bozkurt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Aguilar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Allen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Byun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Colvin</surname></persName>
		</author>
		<idno type="DOI">10.1161/cir.0000000000001063</idno>
		<idno>Medline: 35363499</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Bh572UA">Circulation</title>
		<imprint>
			<biblScope unit="volume">03</biblScope>
			<biblScope unit="issue">18</biblScope>
			<biblScope unit="page" from="e895" to="1032" />
			<date type="published" when="2022-05">2022. May. 2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. May 03, 2022;145(18):e895-1032. [FREE Full text] [doi: 10.1161/CIR.0000000000001063] [Medline: 35363499]</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_f9D4Rp2">ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Mcdonagh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Metra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Adamo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Gardner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Baumbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>BÃ¶hm</surname></persName>
		</author>
		<idno type="DOI">10.1093/eurheartj/ehab368</idno>
		<idno>Medline: 34447992</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_KyTjSjt">Eur Heart J. Sep</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">36</biblScope>
			<biblScope unit="page" from="3599" to="3726" />
			<date type="published" when="2021">2021. 2021</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, BÃ¶hm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. Sep 21, 2021;42(36):3599-3726. [FREE Full text] [doi: 10.1093/eurheartj/ehab368] [Medline: 34447992]</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_mns62vq">Economic evaluation of the utilization of telemedicine for patients with cardiovascular disease: a systematic review</title>
		<author>
			<persName><forename type="first">H</forename><surname>Farabi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rezapour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jahangiri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jafari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rashki</forename><surname>Kemmak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nikjoo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
		<idno type="DOI">10.1007/s10741-019-09864-4</idno>
		<idno>Medline: 31760593</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_KDTuURn">Heart Fail Rev. Nov</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1063" to="1075" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Farabi H, Rezapour A, Jahangiri R, Jafari A, Rashki Kemmak A, Nikjoo S. Economic evaluation of the utilization of telemedicine for patients with cardiovascular disease: a systematic review. Heart Fail Rev. Nov 23, 2020;25(6):1063-1075. [doi: [Medline: 31760593]</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_68qchbU">The cost-effectiveness of digital health interventions on the management of cardiovascular diseases: systematic review</title>
		<author>
			<persName><forename type="first">X</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Ming</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>You</surname></persName>
		</author>
		<idno type="DOI">10.2196/13166</idno>
		<idno>Medline: 31210136</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ptq3H5R">J Med Internet Res. Jun</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page">e13166</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Jiang X, Ming WK, You JH. The cost-effectiveness of digital health interventions on the management of cardiovascular diseases: systematic review. J Med Internet Res. Jun 17, 2019;21(6):e13166. [FREE Full text] [doi: 10.2196/13166] [Medline: 31210136]</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_rrMjTyg">Cost-effectiveness of cardiac telerehabilitation in coronary artery disease and heart failure patients: systematic review of randomized controlled trials</title>
		<author>
			<persName><forename type="first">M</forename><surname>Scherrenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Falter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dendale</surname></persName>
		</author>
		<idno type="DOI">10.1093/ehjdh/ztaa005</idno>
		<idno>Medline: 37056294</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ykdAZJW">Eur Heart J Digit Health</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="20" to="29" />
			<date type="published" when="2020-11">Nov 2020</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Scherrenberg M, Falter M, Dendale P. Cost-effectiveness of cardiac telerehabilitation in coronary artery disease and heart failure patients: systematic review of randomized controlled trials. Eur Heart J Digit Health. Nov 2020;1(1):20-29. [FREE Full text] [doi: 10.1093/ehjdh/ztaa005] [Medline: 37056294]</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_22DnUd7">The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Page</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Mckenzie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Bossuyt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Boutron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Hoffmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Mulrow</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.n71</idno>
		<idno>Medline: 33782057</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_gc3rsXy">BMJ. Mar</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. Mar 29, 2021;372:n71. [FREE Full text] [doi: 10.1136/bmj.n71] [Medline: 33782057]</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_Jry7EY4">Economic evaluation of digital health interventions for patients with heart failure: a systematic review</title>
		<author>
			<persName><forename type="first">D</forename><surname>Marulin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Puspitasari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Zakiyah</surname></persName>
		</author>
		<ptr target="https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=388241" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_mBSUvDR">PROSPERO</title>
		<imprint>
			<date type="published" when="2023-02-10">2023. 2023-02-10</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Marulin D, Puspitasari IM, Zakiyah N. Economic evaluation of digital health interventions for patients with heart failure: a systematic review. PROSPERO. 2023. URL: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=388241 [accessed 2023-02-10]</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_qNmfs7q">Recommendations on digital interventions for health system strengthening</title>
		<ptr target="https://www.who.int/publications/i/item/9789241550505" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_WjEAtgX">World Health Organization</title>
		<imprint>
			<date type="published" when="2019-07-06">Jul 6, 2019. 2024-04-12</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Recommendations on digital interventions for health system strengthening. World Health Organization. Jul 6, 2019. URL: https://www.who.int/publications/i/item/9789241550505 [accessed 2024-04-12]</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_7njmxny">Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations</title>
		<author>
			<persName><forename type="first">D</forename><surname>Husereau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Drummond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Augustovski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>De Bekker-Grob</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Briggs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Carswell</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jval.2021.11.1351</idno>
		<idno>Medline: 35031096</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9ASaaQ8">Value Health</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="3" to="9" />
			<date type="published" when="2022-01">Jan 2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. Jan 2022;25(1):3-9. [FREE Full text] [doi: 10.1016/j.jval.2021.11.1351] [Medline: 35031096]</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main" xml:id="_k9bsKnQ">Economic evaluation of family planning interventions in low and middle income countries; a systematic review</title>
		<author>
			<persName><forename type="first">N</forename><surname>Zakiyah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Van Asselt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Roijmans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Postma</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0168447</idno>
		<idno>Medline: 27992552</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bSJuRym">PLoS One</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page">168447</biblScope>
			<date type="published" when="2016-12-19">Dec 19. 2016</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Zakiyah N, van Asselt AD, Roijmans F, Postma MJ. Economic evaluation of family planning interventions in low and middle income countries; a systematic review. PLoS One. Dec 19, 2016;11(12):e0168447. [FREE Full text] [doi: 10.1371/journal.pone.0168447] [Medline: 27992552]</note>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<idno type="DOI">10.1093/benz/9780199773787.article.b00059286</idno>
		<ptr target="https://eppi.ioe.ac.uk/costconversion" />
		<title level="m" xml:id="_Yc6AVve">CCEMG -EPPI-Centre cost converter</title>
		<imprint>
			<publisher>EPPI Centre</publisher>
			<date type="published" when="2022-04-10">2022-04-10</date>
		</imprint>
	</monogr>
	<note type="raw_reference">CCEMG -EPPI-Centre cost converter. EPPI Centre. URL: https://eppi.ioe.ac.uk/costconversion [accessed 2022-04-10]</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_3HHMjDb">Summarising economic evaluations in systematic reviews: a new approach</title>
		<author>
			<persName><forename type="first">J</forename><surname>Nixon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Khan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kleijnen</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.322.7302.1596</idno>
		<idno>Medline: 11431306</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rYKRW9v">BMJ. Jun</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">7302</biblScope>
			<biblScope unit="page" from="1596" to="1598" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Nixon J, Khan KS, Kleijnen J. Summarising economic evaluations in systematic reviews: a new approach. BMJ. Jun 30, 2001;322(7302):1596-1598. [FREE Full text] [doi: 10.1136/bmj.322.7302.1596] [Medline: 11431306]</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_PJq2rUj">A telemonitoring programme in patients with heart failure in France: a cost-utility analysis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Caillon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sabatier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Legallois</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Courouve</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Donio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Boudevin</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12872-022-02878-1</idno>
		<idno>Medline: 36217130</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6xaTRPv">BMC Cardiovasc Disord</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">441</biblScope>
			<date type="published" when="2022-10-10">Oct 10. 2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Caillon M, Sabatier R, Legallois D, Courouve L, Donio V, Boudevin F, et al. A telemonitoring programme in patients with heart failure in France: a cost-utility analysis. BMC Cardiovasc Disord. Oct 10, 2022;22(1):441. [FREE Full text] [doi: 10.1186/s12872-022-02878-1] [Medline: 36217130]</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_RQGb8Xy">Telemonitoring after discharge from hospital with heart failure: cost-effectiveness modelling of alternative service designs</title>
		<author>
			<persName><forename type="first">P</forename><surname>Thokala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Baalbaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Brennan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pandor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Stevens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gomersall</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmjopen-2013-003250</idno>
		<idno>Medline: 24048626</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_NV87xkf">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page">3250</biblScope>
			<date type="published" when="2013-09-18">Sep 18, 2013</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Thokala P, Baalbaki H, Brennan A, Pandor A, Stevens JW, Gomersall T, et al. Telemonitoring after discharge from hospital with heart failure: cost-effectiveness modelling of alternative service designs. BMJ Open. Sep 18, 2013;3(9):e003250. [FREE Full text] [doi: 10.1136/bmjopen-2013-003250] [Medline: 24048626]</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main" xml:id="_zdz5HtU">Home telemonitoring and a diagnostic algorithm in the management of heart failure in the Netherlands: cost-effectiveness analysis</title>
		<author>
			<persName><forename type="first">Albuquerque</forename><surname>De Almeida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Corro</forename><surname>Ramos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Al</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rutten-Van MÃ¶lken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<idno type="DOI">10.2196/31302</idno>
		<idno>Medline: 35925670</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ykwkEKg">JMIR Cardio</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">31302</biblScope>
			<date type="published" when="2022-08-04">Aug 04, 2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Albuquerque de Almeida F, Corro Ramos I, Al M, Rutten-van MÃ¶lken M. Home telemonitoring and a diagnostic algorithm in the management of heart failure in the Netherlands: cost-effectiveness analysis. JMIR Cardio. Aug 04, 2022;6(2):e31302. [FREE Full text] [doi: 10.2196/31302] [Medline: 35925670]</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_XJPRvCH">Telemonitoring versus usual care for elderly patients with heart failure discharged from the hospital in the United States: cost-effectiveness analysis</title>
		<author>
			<persName><forename type="first">X</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>You</surname></persName>
		</author>
		<idno type="DOI">10.2196/17846</idno>
		<idno>Medline: 32407288</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pyBAT8d">JMIR Mhealth Uhealth</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page">17846</biblScope>
			<date type="published" when="2020-07-06">Jul 06, 2020</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Jiang X, Yao J, You JH. Telemonitoring versus usual care for elderly patients with heart failure discharged from the hospital in the United States: cost-effectiveness analysis. JMIR Mhealth Uhealth. Jul 06, 2020;8(7):e17846. [FREE Full text] [doi: 10.2196/17846] [Medline: 32407288]</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main" xml:id="_egkZyzY">Developing Markov models from real-world data: a case study of heart failure modeling using administrative data</title>
		<author>
			<persName><forename type="first">P</forename><surname>Thokala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dodd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Baalbaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Brennan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dixon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Lowrie</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jval.2020.02.012</idno>
		<idno>Medline: 32540232</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wcmrMkg">Value Health</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="743" to="750" />
			<date type="published" when="2020-06">Jun 2020</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Thokala P, Dodd P, Baalbaki H, Brennan A, Dixon S, Lowrie K. Developing Markov models from real-world data: a case study of heart failure modeling using administrative data. Value Health. Jun 2020;23(6):743-750. [FREE Full text] [doi: 10.1016/j.jval.2020.02.012] [Medline: 32540232]</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main" xml:id="_csM5Evv">The first year of noninvasive remote telemonitoring in chronic heart failure is not cost saving but improves quality of life: the randomized controlled CardioBBEAT trial</title>
		<author>
			<persName><forename type="first">H</forename><surname>VÃ¶ller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bindl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nagels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hofmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Vettorazzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wegscheider</surname></persName>
		</author>
		<idno type="DOI">10.1089/tmj.2022.0021</idno>
		<idno>Medline: 35325562</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zRJZUKf">Telemed J E Health</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1613" to="1622" />
			<date type="published" when="2022-03-21">Mar 21. 2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">VÃ¶ller H, Bindl D, Nagels K, Hofmann R, Vettorazzi E, Wegscheider K, et al. The first year of noninvasive remote telemonitoring in chronic heart failure is not cost saving but improves quality of life: the randomized controlled CardioBBEAT trial. Telemed J E Health. Mar 21, 2022;28(11):1613-1622. [FREE Full text] [doi: 10.1089/tmj.2022.0021] [Medline: 35325562]</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main" xml:id="_sheWvrh">Cost-effectiveness analysis of telemonitoring versus usual care in patients with heart failure: the TEHAF-study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Boyne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Di Van Asselt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Gorgels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Steuten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>De Weerd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kragten</surname></persName>
		</author>
		<idno type="DOI">10.1177/1357633x13495478</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_A5wwjTX">J Telemed Telecare</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="242" to="248" />
			<date type="published" when="2016-07-09">Jul 09. 2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Boyne JJ, di van Asselt A, Gorgels AP, Steuten LM, de Weerd G, Kragten J, et al. Cost-effectiveness analysis of telemonitoring versus usual care in patients with heart failure: the TEHAF-study. J Telemed Telecare. Jul 09, 2016;19(5):242-248. [doi: 10.1177/1357633x13495478]</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main" xml:id="_zutPpfY">Cost-effectiveness of noninvasive telemedical interventional management in patients with heart failure: health economic analysis of the TIM-HF2 trial</title>
		<author>
			<persName><forename type="first">H</forename><surname>Sydow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Prescher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Koehler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Koehler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dorenkamp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Spethmann</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00392-021-01980-2</idno>
		<idno>Medline: 34894273</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5HG5jdg">Clin Res Cardiol</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1231" to="1244" />
			<date type="published" when="2022-11-11">Nov 11. 2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Sydow H, Prescher S, Koehler F, Koehler K, Dorenkamp M, Spethmann S, et al. Cost-effectiveness of noninvasive telemedical interventional management in patients with heart failure: health economic analysis of the TIM-HF2 trial. Clin Res Cardiol. Nov 11, 2022;111(11):1231-1244. [FREE Full text] [doi: 10.1007/s00392-021-01980-2] [Medline: 34894273]</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main" xml:id="_2t73A2E">Is telehealthcare for heart failure patients cost-effective? An economic evaluation alongside the Danish TeleCare North heart failure trial</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Vestergaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>SÃ¸rensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Ehlers</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmjopen-2019-031670</idno>
		<idno>Medline: 31992604</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_D7DAhGy">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">31670</biblScope>
			<date type="published" when="2020-01-27">Jan 27. 2020</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Vestergaard AS, Hansen L, SÃ¸rensen SS, Jensen MB, Ehlers LH. Is telehealthcare for heart failure patients cost-effective? An economic evaluation alongside the Danish TeleCare North heart failure trial. BMJ Open. Jan 27, 2020;10(1):e031670. [FREE Full text] [doi: 10.1136/bmjopen-2019-031670] [Medline: 31992604]</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main" xml:id="_63SJfg6">Cost-effectiveness analysis in telehealth: a comparison between home telemonitoring, nurse telephone support, and usual care in chronic heart failure management</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Grustam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Severens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>De Massari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Buyukkaramikli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Koymans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Vrijhoef</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jval.2017.11.011</idno>
		<idno>Medline: 30005749</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_j9AZBbm">Value Health</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="772" to="782" />
			<date type="published" when="2018-07">Jul 2018</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Grustam AS, Severens JL, de Massari D, Buyukkaramikli N, Koymans R, Vrijhoef HJ. Cost-effectiveness analysis in telehealth: a comparison between home telemonitoring, nurse telephone support, and usual care in chronic heart failure management. Value Health. Jul 2018;21(7):772-782. [FREE Full text] [doi: 10.1016/j.jval.2017.11.011] [Medline: 30005749]</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main" xml:id="_xQTQMV7">Cost-effectiveness of a home visit program for patients with heart failure in Brazil: evidence from a randomized clinical trial</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Ruschel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Rabelo-Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Rohde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">N</forename><surname>De Souza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Mussi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Polanczyk</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.vhri.2018.03.006</idno>
		<idno>Medline: 29754015</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_MAT4b6p">Value Health Reg Issues</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="81" to="87" />
			<date type="published" when="2018-12">Dec 2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ruschel KB, Rabelo-Silva ER, Rohde LE, de Souza EN, Mussi CM, Polanczyk CA. Cost-effectiveness of a home visit program for patients with heart failure in Brazil: evidence from a randomized clinical trial. Value Health Reg Issues. Dec 2018;17:81-87. [doi: 10.1016/j.vhri.2018.03.006] [Medline: 29754015]</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main" xml:id="_CgY8muV">Economic evaluation of Manitoba Health Lines in the management of congestive heart failure</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Doupe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Katz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Nyhof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Forget</surname></persName>
		</author>
		<idno type="DOI">10.12927/hcpol.2013.23620</idno>
		<idno>Medline: 24359716</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_qxQ4Hfa">Healthc Policy</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="36" to="50" />
			<date type="published" when="2013-11">Nov 2013</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Cui Y, Doupe M, Katz A, Nyhof P, Forget EL. Economic evaluation of Manitoba Health Lines in the management of congestive heart failure. Healthc Policy. Nov 2013;9(2):36-50. [FREE Full text] [Medline: 24359716]</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main" xml:id="_mqtmDdX">Cost-effectiveness of nurse-led disease management for heart failure in an ethnically diverse urban community</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Hebert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Sisk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Tuzzio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Casabianca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Chassin</surname></persName>
		</author>
		<idno type="DOI">10.7326/0003-4819-149-8-200810210-00006</idno>
		<idno>Medline: 18936502</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wsnNkQK">Ann Intern Med. Oct</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="540" to="548" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Hebert PL, Sisk JE, Wang JJ, Tuzzio L, Casabianca JM, Chassin MR, et al. Cost-effectiveness of nurse-led disease management for heart failure in an ethnically diverse urban community. Ann Intern Med. Oct 21, 2008;149(8):540-548. [FREE Full text] [doi: 10.7326/0003-4819-149-8-200810210-00006] [Medline: 18936502]</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main" xml:id="_gv78Y6U">Cost-effectiveness of telephonic disease management in heart failure</title>
		<author>
			<persName><forename type="first">B</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">F</forename><surname>Hughes-Cromwick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Forkner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Galbreath</surname></persName>
		</author>
		<idno>Medline: 18269306</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_E8es5CP">Am J Manag Care</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="106" to="115" />
			<date type="published" when="2008-02">Feb 2008</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Smith B, Hughes-Cromwick PF, Forkner E, Galbreath AD. Cost-effectiveness of telephonic disease management in heart failure. Am J Manag Care. Feb 2008;14(2):106-115. [FREE Full text] [Medline: 18269306]</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main" xml:id="_eK3pr6p">Cost-effectiveness benefits of a disease management program: the REMADHE trial results</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Bocchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">D</forename><surname>Da Cruz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>BrandÃ£o</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Issa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Ayub-Ferreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Brunner La Rocca</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cardfail.2018.04.008</idno>
		<idno>Medline: 29723595</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WhbrBtJ">J Card Fail</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="627" to="637" />
			<date type="published" when="2018-10">Oct 2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bocchi EA, da Cruz FD, BrandÃo SM, Issa V, Ayub-Ferreira SM, Brunner la Rocca HP, et al. Cost-effectiveness benefits of a disease management program: the REMADHE trial results. J Card Fail. Oct 2018;24(10):627-637. [doi: 10.1016/j.cardfail.2018.04.008] [Medline: 29723595]</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main" xml:id="_pqBsQ2P">Cost-effectiveness of a follow-up program for older patients with heart failure: a randomized controlled trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>GonzÃ¡lez-Guerrero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>HernÃ¡ndez-Mocholi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Ribera-Casado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>GarcÃ­a-MayolÃ­n</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Alonso-FernÃ¡ndez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Gusi</surname></persName>
		</author>
		<idno type="DOI">10.1007/s41999-018-0074-y</idno>
		<idno>Medline: 34674493</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9DDphTX">Eur Geriatr Med</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="523" to="532" />
			<date type="published" when="2018-08-06">Aug 06. 2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">GonzÃ¡lez-Guerrero JL, HernÃ¡ndez-Mocholi MA, Ribera-Casado JM, GarcÃ­a-MayolÃ­n N, Alonso-FernÃ¡ndez T, Gusi N. Cost-effectiveness of a follow-up program for older patients with heart failure: a randomized controlled trial. Eur Geriatr Med. Aug 06, 2018;9(4):523-532. [doi: 10.1007/s41999-018-0074-y] [Medline: 34674493]</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main" xml:id="_setBXsn">Cost-effectiveness of a telemonitoring program for patients with heart failure during the COVID-19 pandemic in Hong Kong: model development and data analysis</title>
		<author>
			<persName><forename type="first">X</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>You</surname></persName>
		</author>
		<idno type="DOI">10.2196/26516</idno>
		<idno>Medline: 33656440</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7mJ4xER">J Med Internet Res. Mar</title>
		<imprint>
			<biblScope unit="volume">03</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">26516</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Jiang X, Yao J, You JH. Cost-effectiveness of a telemonitoring program for patients with heart failure during the COVID-19 pandemic in Hong Kong: model development and data analysis. J Med Internet Res. Mar 03, 2021;23(3):e26516. [FREE Full text] [doi: 10.2196/26516] [Medline: 33656440]</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main" xml:id="_gRaefAP">Evaluation of a heart failure telemonitoring program through a microsimulation model: cost-utility analysis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Boodoo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Ross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Alba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Laporte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Seto</surname></persName>
		</author>
		<idno type="DOI">10.2196/18917</idno>
		<idno>Medline: 33021485</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7c7pxxW">J Med Internet Res</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page">18917</biblScope>
			<date type="published" when="2020-10-06">Oct 06. 2020</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Boodoo C, Zhang Q, Ross HJ, Alba AC, Laporte A, Seto E. Evaluation of a heart failure telemonitoring program through a microsimulation model: cost-utility analysis. J Med Internet Res. Oct 06, 2020;22(10):e18917. [FREE Full text] [doi: 10.2196/18917] [Medline: 33021485]</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main" xml:id="_NsQfj2h">Economic impact assessment from the use of a mobile app for the self-management of heart diseases by patients with heart failure in a Spanish region</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Cano MartÃ­n</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>MartÃ­nez-PÃ©rez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>De La Torre-DÃ­ez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">LÃ³pez-</forename><surname>Coronado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<idno type="DOI">10.1007/s10916-014-0096-z</idno>
		<idno>Medline: 24994514</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FDYSyH5">J Med Syst</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="96" to="97" />
			<date type="published" when="2014-09">Sep 2014</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Cano MartÃ­n JA, MartÃ­nez-PÃ©rez B, de la Torre-DÃ­ez I, LÃ³pez-Coronado M. Economic impact assessment from the use of a mobile app for the self-management of heart diseases by patients with heart failure in a Spanish region. J Med Syst. Sep 2014;38(9):96-97. [FREE Full text] [doi: 10.1007/s10916-014-0096-z] [Medline: 24994514]</note>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main" xml:id="_KRra2kT">The cost-effectiveness of real-time pulmonary artery pressure monitoring in heart failure patients: a European perspective</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Cowie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Simon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Thokala</surname></persName>
		</author>
		<idno type="DOI">10.1002/ejhf.747</idno>
		<idno>Medline: 28176424</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_2VJGedA">Eur J Heart Fail</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="661" to="669" />
			<date type="published" when="2017-05-07">May 07. 2017</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Cowie MR, Simon M, Klein L, Thokala P. The cost-effectiveness of real-time pulmonary artery pressure monitoring in heart failure patients: a European perspective. Eur J Heart Fail. May 07, 2017;19(5):661-669. [FREE Full text] [doi: 10.1002/ejhf.747] [Medline: 28176424]</note>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main" xml:id="_WKxGYHj">Cost-effectiveness of remote cardiac monitoring with the CardioMEMS heart failure system</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Schmier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Ong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">C</forename><surname>Fonarow</surname></persName>
		</author>
		<idno type="DOI">10.1002/clc.22696</idno>
		<idno>Medline: 28272808</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4jSmeCe">Clin Cardiol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="430" to="436" />
			<date type="published" when="2017-07-08">Jul 08. 2017</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Schmier JK, Ong KL, Fonarow GC. Cost-effectiveness of remote cardiac monitoring with the CardioMEMS heart failure system. Clin Cardiol. Jul 08, 2017;40(7):430-436. [FREE Full text] [doi: 10.1002/clc.22696] [Medline: 28272808]</note>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main" xml:id="_RK3Uf39">Cost-effectiveness of implantable pulmonary artery pressure monitoring in chronic heart failure</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Sandhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Goldhaber-Fiebert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Owens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Turakhia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Kaiser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Heidenreich</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jchf.2015.12.015</idno>
		<idno>Medline: 26874380</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ze6a9ds">JACC Heart Fail</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="368" to="375" />
			<date type="published" when="2016-05">May 2016</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Sandhu AT, Goldhaber-Fiebert JD, Owens DK, Turakhia MP, Kaiser DW, Heidenreich PA. Cost-effectiveness of implantable pulmonary artery pressure monitoring in chronic heart failure. JACC Heart Fail. May 2016;4(5):368-375. [FREE Full text] [doi: 10.1016/j.jchf.2015.12.015] [Medline: 26874380]</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main" xml:id="_4Jz2Qwh">Pulmonary artery pressure-guided heart failure management: US cost-effectiveness analyses using the results of the CHAMPION clinical trial</title>
		<author>
			<persName><forename type="first">M</forename><surname>Martinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bharmi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Dalal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">T</forename><surname>Abraham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">B</forename><surname>Adamson</surname></persName>
		</author>
		<idno type="DOI">10.1002/ejhf.642</idno>
		<idno>Medline: 27647784</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_AZvNCfU">Eur J Heart Fail</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="652" to="660" />
			<date type="published" when="2017-05">May 2017</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Martinson M, Bharmi R, Dalal N, Abraham WT, Adamson PB. Pulmonary artery pressure-guided heart failure management: US cost-effectiveness analyses using the results of the CHAMPION clinical trial. Eur J Heart Fail. May 2017;19(5):652-660. [FREE Full text] [doi: 10.1002/ejhf.642] [Medline: 27647784]</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main" xml:id="_gpa8b44">Cost-effectiveness of telerehabilitation in patients with heart failure in Poland: an analysis based on the results of Telerehabilitation in the Heart Failure Patients (TELEREH-HF) randomized clinical trial</title>
		<author>
			<persName><forename type="first">M</forename><surname>Niewada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Tabor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Piotrowicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Piotrowicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Opolski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Banach</surname></persName>
		</author>
		<idno type="DOI">10.33963/kp.15885</idno>
		<idno>Medline: 34125923</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_AKDZ7yx">Kardiol Pol</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="510" to="516" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Niewada M, Tabor B, Piotrowicz E, Piotrowicz R, Opolski G, Banach M, et al. Cost-effectiveness of telerehabilitation in patients with heart failure in Poland: an analysis based on the results of Telerehabilitation in the Heart Failure Patients (TELEREH-HF) randomized clinical trial. Kardiol Pol. 2021;79(5):510-516. [FREE Full text] [doi: 10.33963/KP.15885] [Medline: 34125923]</note>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main" xml:id="_3Hun4t6">Economic impact of remote monitoring on ordinary follow-up of implantable cardioverter defibrillators as compared with conventional in-hospital visits. A single-center prospective and randomized study</title>
		<author>
			<persName><forename type="first">L</forename><surname>CalÃ²</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gargaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>De Ruvo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Palozzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sciarra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rebecchi</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10840-013-9783-9</idno>
		<idno>Medline: 23515883</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wsr2bBP">J Interv Card Electrophysiol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="69" to="78" />
			<date type="published" when="2013-06-21">Jun 21. 2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">CalÃ² L, Gargaro A, de Ruvo E, Palozzi G, Sciarra L, Rebecchi M, et al. Economic impact of remote monitoring on ordinary follow-up of implantable cardioverter defibrillators as compared with conventional in-hospital visits. A single-center prospective and randomized study. J Interv Card Electrophysiol. Jun 21, 2013;37(1):69-78. [doi: 10.1007/s10840-013-9783-9] [Medline: 23515883]</note>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main" xml:id="_mzF5Qtp">Cost-utility analysis of the EVOLVO study on remote monitoring for heart failure patients with implantable defibrillators: randomized controlled trial</title>
		<author>
			<persName><forename type="first">P</forename><surname>Zanaboni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Landolina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Marzegalli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lunati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">B</forename><surname>Perego</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Guenzati</surname></persName>
		</author>
		<idno type="DOI">10.2196/jmir.2587</idno>
		<idno>Medline: 23722666</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_yhekW97">J Med Internet Res</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page">e106</biblScope>
			<date type="published" when="2013-05">May. 2013</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Zanaboni P, Landolina M, Marzegalli M, Lunati M, Perego GB, Guenzati G, et al. Cost-utility analysis of the EVOLVO study on remote monitoring for heart failure patients with implantable defibrillators: randomized controlled trial. J Med Internet Res. May 30, 2013;15(5):e106. [FREE Full text] [doi: 10.2196/jmir.2587] [Medline: 23722666]</note>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main" xml:id="_eNkGYr4">Cost-utility analysis of home-based telerehabilitation compared with centre-based rehabilitation in patients with heart failure</title>
		<author>
			<persName><forename type="first">R</forename><surname>Hwang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">R</forename><surname>Morris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mandrusiak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bruning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Korczyk</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.hlc.2018.11.010</idno>
		<idno>Medline: 30528811</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Y9ECR6b">Heart Lung Circ</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1795" to="1803" />
			<date type="published" when="2019-12">Dec 2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hwang R, Morris NR, Mandrusiak A, Bruning J, Peters R, Korczyk D, et al. Cost-utility analysis of home-based telerehabilitation compared with centre-based rehabilitation in patients with heart failure. Heart Lung Circ. Dec 2019;28(12):1795-1803. [doi: 10.1016/j.hlc.2018.11.010] [Medline: 30528811]</note>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main" xml:id="_TBMfDtf">Cost-consequence analysis of daily continuous remote monitoring of implantable cardiac defibrillator and resynchronization devices in the UK</title>
		<author>
			<persName><forename type="first">H</forename><surname>Burri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sticherling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wright</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Makino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Smala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Tilden</surname></persName>
		</author>
		<idno type="DOI">10.1093/europace/eut070</idno>
		<idno>Medline: 23599169</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_yQkuKRg">Europace</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1601" to="1608" />
			<date type="published" when="2013-11">Nov 2013</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Burri H, Sticherling C, Wright D, Makino K, Smala A, Tilden D. Cost-consequence analysis of daily continuous remote monitoring of implantable cardiac defibrillator and resynchronization devices in the UK. Europace. Nov 2013;15(11):1601-1608. [FREE Full text] [doi: 10.1093/europace/eut070] [Medline: 23599169]</note>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main" xml:id="_rmA9mEx">Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">T</forename><surname>Abraham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">B</forename><surname>Adamson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Bourge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Aaron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Costanzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W</forename><surname>Stevenson</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0140-6736(11)60101-3</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bYrQHNm">The Lancet</title>
		<imprint>
			<biblScope unit="volume">377</biblScope>
			<biblScope unit="page" from="658" to="666" />
			<date type="published" when="2011-02">Feb 2011. 9766</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. The Lancet. Feb 2011;377(9766):658-666. [doi: 10.1016/s0140-6736(11)60101-3]</note>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main" xml:id="_mqC6335">Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial</title>
		<author>
			<persName><forename type="first">F</forename><surname>Koehler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Koehler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Deckwart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Prescher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wegscheider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Kirwan</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0140-6736(18)31880-4</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bPJPMPG">The Lancet</title>
		<imprint>
			<biblScope unit="volume">392</biblScope>
			<biblScope unit="issue">10152</biblScope>
			<biblScope unit="page" from="1047" to="1057" />
			<date type="published" when="2018-09">Sep 2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Koehler F, Koehler K, Deckwart O, Prescher S, Wegscheider K, Kirwan BA, et al. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. The Lancet. Sep 2018;392(10152):1047-1057. [doi: 10.1016/s0140-6736(18)31880-4]</note>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main" xml:id="_G33tAhH">ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ponikowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Voors</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Bueno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cleland</forename><forename type="middle">J</forename><surname>Coats</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
		<idno type="DOI">10.1093/eurheartj/ehw128</idno>
		<idno>Medline: 27206819</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pxdW9Qu">Eur Heart J. Jul</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">27</biblScope>
			<biblScope unit="page" from="2129" to="2200" />
			<date type="published" when="2016">2016. 2016</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Ponikowski P, Voors A, Anker S, Bueno H, Cleland J, Coats A, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. Jul 14, 2016;37(27):2129-2200. [FREE Full text] [doi: 10.1093/eurheartj/ehw128] [Medline: 27206819]</note>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main" xml:id="_fYrpeDj">Correction to: 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America</title>
		<idno type="DOI">10.1161/cir.0000000000000460</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_T6wMfHA">Circulation</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page">e298</biblScope>
			<date type="published" when="2016-09-27">Sep 27, 2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">-. Correction to: 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America. Circulation. Sep 27, 2016;134(13):e298. [doi: 10.1161/CIR.0000000000000460]</note>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main" xml:id="_AcaY5V4">Structured telephone support or non-invasive telemonitoring for patients with heart failure</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Inglis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Clark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dierckx</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Prieto-Merino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cleland</forename><forename type="middle">Jg</forename></persName>
		</author>
		<idno type="DOI">10.1002/14651858.CD007228.pub3</idno>
		<idno>Medline: 26517969</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9BvS2gs">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page">7228</biblScope>
			<date type="published" when="2015-10-31">Oct 31, 2015. 2015</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Inglis SC, Clark RA, Dierckx R, Prieto-Merino D, Cleland JG. Structured telephone support or non-invasive telemonitoring for patients with heart failure. Cochrane Database Syst Rev. Oct 31, 2015;2015(10):CD007228. [FREE Full text] [doi: 10.1002/14651858.CD007228.pub3] [Medline: 26517969]</note>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main" xml:id="_92NJ5M5">Remote monitoring of patients with heart failure: an overview of systematic reviews</title>
		<author>
			<persName><forename type="first">N</forename><surname>Bashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Karunanithi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fatehi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Walters</surname></persName>
		</author>
		<idno type="DOI">10.2196/jmir.6571</idno>
		<idno>Medline: 28108430</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_apxVnzc">J Med Internet Res</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">e18</biblScope>
			<date type="published" when="2017-01-20">Jan 20. 2017</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Bashi N, Karunanithi M, Fatehi F, Ding H, Walters D. Remote monitoring of patients with heart failure: an overview of systematic reviews. J Med Internet Res. Jan 20, 2017;19(1):e18. [FREE Full text] [doi: 10.2196/jmir.6571] [Medline: 28108430]</note>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main" xml:id="_6Vqdp26">Economic evaluation of digital health interventions: methodological issues and recommendations for practice</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gomes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Murray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Raftery</surname></persName>
		</author>
		<idno type="DOI">10.1007/s40273-022-01130-0</idno>
		<idno>Medline: 35132606</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_EPbVu7T">Pharmacoeconomics</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="367" to="378" />
			<date type="published" when="2022-04-08">Apr 08, 2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Gomes M, Murray E, Raftery J. Economic evaluation of digital health interventions: methodological issues and recommendations for practice. Pharmacoeconomics. Apr 08, 2022;40(4):367-378. [FREE Full text] [doi: 10.1007/s40273-022-01130-0] [Medline: 35132606]</note>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main" xml:id="_g5XJvNZ">Home telemonitoring or structured telephone support programmes after recent discharge in patients with heart failure: systematic review and economic evaluation</title>
		<author>
			<persName><forename type="first">A</forename><surname>Pandor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Thokala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gomersall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Baalbaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Stevens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.3310/hta17320</idno>
		<idno>Medline: 23927840</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_NpFmbYC">Health Technol Assess</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">32</biblScope>
			<biblScope unit="page" from="1" to="207" />
			<date type="published" when="2013-08">Aug 2013</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Pandor A, Thokala P, Gomersall T, Baalbaki H, Stevens JW, Wang J, et al. Home telemonitoring or structured telephone support programmes after recent discharge in patients with heart failure: systematic review and economic evaluation. Health Technol Assess. Aug 2013;17(32):1-207, v. [FREE Full text] [doi: 10.3310/hta17320] [Medline: 23927840]</note>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main" xml:id="_T45VR9U">Cost comparison between telemonitoring and usual care of heart failure: a systematic review</title>
		<author>
			<persName><forename type="first">E</forename><surname>Seto</surname></persName>
		</author>
		<idno type="DOI">10.1089/tmj.2007.0114</idno>
		<idno>Medline: 18817497</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_gfByssE">Telemed J E Health</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="679" to="686" />
			<date type="published" when="2008-09">Sep 2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Seto E. Cost comparison between telemonitoring and usual care of heart failure: a systematic review. Telemed J E Health. Sep 2008;14(7):679-686. [doi: 10.1089/tmj.2007.0114] [Medline: 18817497]</note>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main" xml:id="_MnuJmZt">Editorial: challenges in implementing digital health in public health settings in low and middle income countries</title>
		<author>
			<persName><forename type="first">M</forename><surname>Duggal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">El</forename><surname>Ayadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Duggal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Reynolds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Bascaran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
		<idno type="DOI">10.3389/fpubh.2022.1090303</idno>
		<idno>Medline: 36703825</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_hssx98B">Front Public Health</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">1090303</biblScope>
			<date type="published" when="2022-01-10">Jan 10, 2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Duggal M, El Ayadi A, Duggal B, Reynolds N, Bascaran C. Editorial: challenges in implementing digital health in public health settings in low and middle income countries. Front Public Health. Jan 10, 2022;10:1090303. [FREE Full text] [doi: 10.3389/fpubh.2022.1090303] [Medline: 36703825]</note>
</biblStruct>

<biblStruct xml:id="b68">
	<monogr>
		<title level="m" type="main" xml:id="_nvtCFQ3">Global strategy on digital health</title>
		<idno type="DOI">10.2196/preprints.52150</idno>
		<imprint>
			<date type="published" when="2020">2020-2025</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Global strategy on digital health 2020-2025.</note>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main" xml:id="_BgYtGFe">Barriers and facilitators for the sustainability of digital health interventions in low and middle-income countries: a systematic review</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>KaborÃ©</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ngangue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Soubeiga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Barro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>PilabrÃ©</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Bationo</surname></persName>
		</author>
		<idno type="DOI">10.3389/fdgth.2022.1014375</idno>
		<idno>Medline: 36518563</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_aVz9Xyz">Front Digit Health</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">1014375</biblScope>
			<date type="published" when="2022-11-28">Nov 28. 2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">KaborÃ© SS, Ngangue P, Soubeiga D, Barro A, PilabrÃ© AH, Bationo N, et al. Barriers and facilitators for the sustainability of digital health interventions in low and middle-income countries: a systematic review. Front Digit Health. Nov 28, 2022;4:1014375. [FREE Full text] [doi: 10.3389/fdgth.2022.1014375] [Medline: 36518563]</note>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main" xml:id="_yg6nUqb">Digital health-enabled genomics: opportunities and challenges</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Bombard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Ginsburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Sturm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Lemke</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ajhg.2022.05.001</idno>
		<idno>Medline: 35803232</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7EC5SpA">Am J Hum Genet</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1190" to="1198" />
			<date type="published" when="2022-07-07">Jul 07. 2022</date>
		</imprint>
	</monogr>
	<note>FREE Full text</note>
	<note type="raw_reference">Bombard Y, Ginsburg GS, Sturm AC, Zhou AY, Lemke AA. Digital health-enabled genomics: opportunities and challenges. Am J Hum Genet. Jul 07, 2022;109(7):1190-1198. [FREE Full text] [doi: 10.1016/j.ajhg.2022.05.001] [Medline: 35803232]</note>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main" xml:id="_e2jcJ7D">Towards precision medicine in heart failure</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Weldy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Ashley</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41569-021-00566-9</idno>
		<idno>WTP: willingness-to-pay</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_SdS8GTW">Nat Rev Cardiol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="745" to="762" />
			<date type="published" when="2021-11-09">Nov 09. 2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Weldy CS, Ashley EA. Towards precision medicine in heart failure. Nat Rev Cardiol. Nov 09, 2021;18(11):745-762. [doi: 10.1038/s41569-021-00566-9] [Medline: 34108678] WTP: willingness-to-pay</note>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main" xml:id="_qFGqNUU">submitted 24.10.23; peer-reviewed by D Setiawan</title>
		<author>
			<persName><forename type="first">T</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><surname>Leung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_jthChfK">T Gal</title>
		<imprint/>
	</monogr>
	<note>comments to author 18.03.24 revised version received 26.03.24; accepted 26.03.24 30.04.24 Please cite as</note>
	<note type="raw_reference">Edited by S Ma, T Leung; submitted 24.10.23; peer-reviewed by D Setiawan, T Gal; comments to author 18.03.24; revised version received 26.03.24; accepted 26.03.24; published 30.04.24 Please cite as:</note>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main" xml:id="_svauCaj">Economic Evaluations of Digital Health Interventions for Patients With Heart Failure: Systematic Review</title>
		<author>
			<persName><forename type="first">N</forename><surname>Zakiyah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Marulin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Alfaqeeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Puspitasari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Lestari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fox-Rushby</surname></persName>
		</author>
		<idno type="DOI">10.2196/53500</idno>
		<ptr target="https://www.jmir.org/2024/1/e53500doi:10.2196/53500" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_a4fHrYH">J Med Internet Res</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page">53500</biblScope>
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zakiyah N, Marulin D, Alfaqeeh M, Puspitasari IM, Lestari K, Lim KK, Fox-Rushby J Economic Evaluations of Digital Health Interventions for Patients With Heart Failure: Systematic Review J Med Internet Res 2024;26:e53500 URL: https://www.jmir.org/2024/1/e53500 doi: 10.2196/53500 PMID:</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
